<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003712.pub3" GROUP_ID="VASC" ID="480601070617050166" MERGED_FROM="" MODIFIED="2016-04-12 12:27:30 +0100" MODIFIED_BY="[Empty name]" REVIEW_NO="0008" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2016-04-12 12:27:30 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Transmyocardial laser revascularization versus medical therapy for refractory angina</TITLE>
<CONTACT>
<PERSON ID="19013" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Eduardo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Briones</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION>Epidemiologist</POSITION>
<EMAIL_1>briones@cica.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Public Health Unit</DEPARTMENT>
<ORGANISATION>Primary Care District. IBIS-CIBERESP</ORGANISATION>
<ADDRESS_1>Avda Jerez s/n</ADDRESS_1>
<ADDRESS_2>Antiguo Hospital Militar</ADDRESS_2>
<CITY>Sevilla</CITY>
<ZIP>41014</ZIP>
<REGION>Sevilla</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34663025379</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-04-12 12:21:58 +0100" MODIFIED_BY="Nicole Martin">
<PERSON ID="19013" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Eduardo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Briones</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION>Epidemiologist</POSITION>
<EMAIL_1>briones@cica.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Public Health Unit</DEPARTMENT>
<ORGANISATION>Primary Care District. IBIS-CIBERESP</ORGANISATION>
<ADDRESS_1>Avda Jerez s/n</ADDRESS_1>
<ADDRESS_2>Antiguo Hospital Militar</ADDRESS_2>
<CITY>Sevilla</CITY>
<ZIP>41014</ZIP>
<REGION>Sevilla</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34663025379</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13875" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Juan Ramon</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lacalle</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>jralex@us.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Preventive Medicine and Public Health</DEPARTMENT>
<ORGANISATION>Universidad de Sevilla</ORGANISATION>
<ADDRESS_1>Avenida Sanchez Pizjuan</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sevilla</CITY>
<ZIP>41009</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 95 455 7875</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="E515A9AE82E26AA200CD32E5DEE79794" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Ignacio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Marin-Leon</LAST_NAME>
<SUFFIX/>
<POSITION>Internal Medicine Senior</POSITION>
<EMAIL_1>ignacio.marin.sspa@juntadeandalucia.es</EMAIL_1>
<EMAIL_2>palomanacho@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE>+34 60 000 08 72</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Internal Medicine</DEPARTMENT>
<ORGANISATION>Hospital Universitario Virgen del Rocio, IBIS-CIBERESP</ORGANISATION>
<ADDRESS_1>Manuel Siurot, Office 2nd floor</ADDRESS_1>
<ADDRESS_2/>
<CITY>Sevilla</CITY>
<ZIP>41013</ZIP>
<REGION/>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 600000872</PHONE_1>
<PHONE_2/>
<FAX_1>+34 95 469 3757</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="1BC78FA582E26AA200CF0384DB5FCFBE" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>José-Ramón</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rueda</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Teacher</POSITION>
<EMAIL_1>joseramon.rueda@ehu.es</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+34-656734086</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Preventive Medicine and Public Health</DEPARTMENT>
<ORGANISATION>University of the Basque Country</ORGANISATION>
<ADDRESS_1>Barrio Sarriena</ADDRESS_1>
<ADDRESS_2>S.N.</ADDRESS_2>
<CITY>Leioa</CITY>
<ZIP>E-48080</ZIP>
<REGION>Bizkaia</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 94 601 3421</PHONE_1>
<PHONE_2/>
<FAX_1>+34 94 601 3393</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-02-12 10:06:35 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="11" MONTH="6" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="6" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="11" MONTH="6" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2002"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2016-04-12 12:27:30 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2016-04-12 12:27:30 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="4" YEAR="2016"/>
<DESCRIPTION>
<P>No new trials since 2004 and no known ongoing trials.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-04-12 12:23:45 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-04-12 12:23:45 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>New search run and no new studies found for inclusion; therefore there are no changes to the conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-04-12 12:23:43 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="6" YEAR="2014"/>
<DESCRIPTION>
<P>We added a new author and included 'Risk of bias' tables and a 'Summary of findings' table. We also added a 'Risk of bias' graph and 'Risk of bias' summary figure.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-06-26 13:42:54 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Andalusian Agency for Health Technology Assessment</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Seville</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Andalusian Health Service</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-02-25 09:13:22 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-02-10 04:39:52 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2015-02-09 04:43:27 +0000" MODIFIED_BY="[Empty name]">Transmyocardial laser revascularization compared to medical therapy for refractory angina</TITLE>
<SUMMARY_BODY MODIFIED="2015-02-10 04:39:52 +0000" MODIFIED_BY="[Empty name]">
<P>This review examines the effectiveness and safety of a surgical intervention using a laser device directly on the heart surface for patients suffering from angina for whom other interventions are not suitable. This is an updated version of the original review published in 2009.</P>
<P>Patients with prolonged or recurrent chest pain due to heart disease have different treatment options, such as medication, catheter interventions, or coronary artery surgery. In spite of the optimal use of such treatments, an increasing number of patients progress to advanced disease, becoming less responsive to medical treatment, suffering from more severe symptoms, very limited exercise capacity and poor quality of life. Transmyocardial laser revascularization (TMLR) is a surgical intervention intended to re-establish blood flow in some areas of the heart, using a laser device directly on the heart surface, thereby relieving angina and improving symptoms.</P>
<P>Several studies have been carried out to determine the efficacy and safety of this intervention, but most had important methodological limitations and high risk of performance bias in relation to subjective outcomes such as angina pain. Overall, 43.8% of patients in the group treated with laser had their chest pain improved significantly, compared with 14.8% in the medication group. However, the evaluation of chest pain was performed without blinding (patients and doctors were aware of the intervention) and this may have biased the results. On the other hand, the risk of dying at one year was similar between the groups, but there is an excess risk of early mortality following the intervention in the laser group.</P>
<P>This updated review concludes that there is no evidence of clinical benefits after TMLR, but data on safety suggests that the procedure may pose unacceptable risks. The intervention is becoming obsolete and it is not expected that new research in this field would change this conclusion.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-02-25 08:53:11 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-02-23 19:00:34 +0000" MODIFIED_BY="[Empty name]">
<P>This is an update of a review previously published in 2009. Chronic angina and advanced forms of coronary disease are increasingly more frequent. In spite of the improvement in the efficacy of available revascularization treatments, a subgroup of patients continue suffering from refractory angina. Transmyocardial laser revascularization (TMLR) has been proposed to improve the clinical situation of these patients.<BR/>
</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-02-23 19:04:18 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects (both benefits and harms) of TMLR versus optimal medical treatment in people with refractory angina who are not candidates for percutaneous coronary angioplasty or coronary artery bypass graft, in alleviating angina severity, reducing mortality and improving ejection fraction.<BR/>
</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-02-25 08:49:52 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the following resources up to June 2014: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the metaRegister of Controlled Trials database, ClinicalTrials.gov, and the WHO International Clinical Trials Registry. We applied no languages restrictions. We also checked reference lists of relevant papers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-02-10 03:51:03 +0000" MODIFIED_BY="[Empty name]">
<P>We selected studies if they fulfilled the following criteria: randomized controlled trials (RCTs) of TMLR, by thoracotomy, in patients with Canadian Cardiovascular Society or New York Heart Association angina grade III-IV who were excluded from other revascularization procedures.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-02-11 01:53:06 +0000" MODIFIED_BY="[Empty name]">
<P>Three authors independently extracted data for each trial about the population and interventions compared and assessed the risk of bias of the studies, evaluating randomisation sequence generation, allocation concealment, blinding (of participants, personnel and outcome assessors), incomplete outcome data, selective outcome reporting, and other potential sources of bias.<BR/>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-02-25 08:53:11 +0000" MODIFIED_BY="[Empty name]">
<P>From a total of 502 references, we retrieved 47 papers for more detailed evaluation. We selected 20 papers, reporting data from seven studies, which included 1137 participants, of which 559 were randomized to TMLR. Participants and professionals were not blinded, which suggests high risk of performance bias. Overall, 43.8% of participants in the treatment group decreased two angina classes, as compared with 14.8% in the control group: odds ratio (OR) 4.63, 95% confidence interval (CI) 3.43 to 6.25), and heterogeneity was present. Mortality by intention-to-treat analysis was similar in both groups at 30 days (4.0% in the TMLR group and 3.5% in the control group), and one year (12.2% in the TMLR group and 11.9% in the control group). However, the 30-day mortality as-treated was 6.8% in the TMLR group and 0.8% in the control group (pooled OR was 3.76, 95% CI 1.63 to 8.66), mainly due to a higher mortality in participants crossing from standard treatment to TMLR. The assessment of subjective outcomes, such as improvement in angina, was affected by a high risk of bias and this may explain the differences found. Other adverse events such as myocardial infarction, arrhythmias or heart failure, were not considered in this review, as they were not predefined outcomes in trials design and they show a high inconsistency across studies. No new trials on transmyocardial laser revascularization have been published in the last ten years and it is very unlikely that new research will be undertaken in this field.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-02-10 04:32:16 +0000" MODIFIED_BY="[Empty name]">
<P>This review shows that risks associated with TMLR outweigh the potential clinical benefits. Subjective outcomes are subject to high risk of bias and no differences were found in survival, but a significant increase in postoperative mortality and other safety outcomes suggests that the procedure may pose unacceptable risks.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-02-25 09:13:22 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-02-25 09:02:22 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-02-25 09:01:18 +0000" MODIFIED_BY="[Empty name]">
<P>Ischaemic heart disease may become apparent and develop in very different ways. Acute and fatal presentations have attracted much attention, but chronic angina and advanced forms are becoming increasingly more relevant, probably associated with increasing patients' survival and improvements in medical and surgical treatments (<LINK REF="REF-Smolina-2012" TYPE="REFERENCE">Smolina 2012</LINK>; <LINK REF="REF-Wijeysundera-2010" TYPE="REFERENCE">Wijeysundera 2010</LINK>). Most patients with less advanced stages respond adequately to treatment with antianginal medication, percutaneous coronary angioplasty (PTCA) with or without stenting, or coronary artery bypass surgery (CABG). In spite of the optimal use of such treatments, however, some patients with advanced disease present with frequent episodes of angina, limited exercise tolerance, and poor quality of life. Those patients are said to have refractory angina.</P>
<P>It has been estimated that 25,000 to 100,000 new patients may be diagnosed each year in the USA, while the overall prevalence could be between 300,000 and 900,000 patients (<LINK REF="REF-Manchanda-2011" TYPE="REFERENCE">Manchanda 2011</LINK>). Other studies have focused on a wider population suffering from severe chronic angina that may progress to refractory angina, producing estimates between 1% and 4% of the adult population in countries such as Canada and Spain (<LINK REF="REF-Borras-2012" TYPE="REFERENCE">Borras 2012</LINK>; <LINK REF="REF-Jolicoeur-2012" TYPE="REFERENCE">Jolicoeur 2012</LINK>; <LINK REF="REF-Qaseen-2012" TYPE="REFERENCE">Qaseen 2012</LINK>). The wide variability among studies is probably due to lack of a standardized definition, as the diagnosis of refractory angina depends on the lack of revascularization alternatives. Therefore, it may vary in different contexts according to the availability of revascularization technology, appropriateness of medical treatment and other interventions targeted to control anginal pain.</P>
<P>Recently, a more precise definition of refractory angina has been proposed, specifying the reason for revascularization unsuitability, such as microvascular dysfunction, epicardial stenosis or generalized lesions (<LINK REF="REF-Jolicoeur-2012" TYPE="REFERENCE">Jolicoeur 2012</LINK>). A multidisciplinary team should assess the therapeutic options, including intensifying medical treatment, cardiac rehabilitation and patient training and participation in symptoms control (<LINK REF="REF-McGuillion-2012" TYPE="REFERENCE">McGuillion 2012</LINK>). Other options that are available for these patients include spinal cord stimulation, enhanced external counter-pulsation and cognitive-behavioural self management interventions, but there is no good evidence of their effectiveness (<LINK REF="REF-Manchanda-2011" TYPE="REFERENCE">Manchanda 2011</LINK>; <LINK REF="REF-McGuillion-2012" TYPE="REFERENCE">McGuillion 2012</LINK>). Currently, TMLR is considered an option only in very specific cases by clinical practice guidelines (<LINK REF="REF-Fihn-2012" TYPE="REFERENCE">Fihn 2012</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-02-25 09:02:22 +0000" MODIFIED_BY="[Empty name]">
<P>Transmyocardial laser revascularization (TMLR) began to be used in 1983 in association with coronary artery bypass graft as a complementary technique (<LINK REF="REF-Smith-1995" TYPE="REFERENCE">Smith 1995</LINK>). Since then it has been considered as an alternative therapy for patients with refractory angina who were not amenable to conventional revascularization therapies. In these patients, the unsuitability for coronary artery bypass graft or percutaneous coronary angioplasty may be because of diffuse coronary atherosclerosis, distal stenoses, small coronary arteries, or the inability to undergo another coronary artery bypass graft or percutaneous coronary angioplasty (<LINK REF="REF-Burkhoff-2001" TYPE="REFERENCE">Burkhoff 2001</LINK>). Its use spread quickly in the 1990s to several hospitals throughout the world, without sound evidence of its efficacy and safety; this led to the raising of difficult questions by clinicians and health service organizations (<LINK REF="REF-Pr_x00ea_tre-1999" TYPE="REFERENCE">Prêtre 1999</LINK>). A number of preliminary studies were enthusiastic about TMLR, showing a decrease in the severity of angina symptoms in most participants (<LINK REF="REF-Cooley-1996" TYPE="REFERENCE">Cooley 1996</LINK>; <LINK REF="REF-Frazier-1995" TYPE="REFERENCE">Frazier 1995</LINK>; <LINK REF="REF-Horvath-1996" TYPE="REFERENCE">Horvath 1996</LINK>; <LINK REF="REF-Mirhoseini-1993" TYPE="REFERENCE">Mirhoseini 1993</LINK>). These results led to the spread of this technology throughout the world, although none of those studies was randomized (<LINK REF="REF-Caine-1998" TYPE="REFERENCE">Caine 1998</LINK>). Since 1999, several randomized controlled trials (RCTs) have been published, reporting contradictory results (<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK>; <LINK REF="STD-Burkhoff-1999" TYPE="STUDY">Burkhoff 1999</LINK>; <LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>; <LINK REF="STD-Jones-1999" TYPE="STUDY">Jones 1999</LINK>; <LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>; <LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>) and generating some debate on methodological issues (<LINK REF="REF-Downing-2000" TYPE="REFERENCE">Downing 2000</LINK>; <LINK REF="REF-Pr_x00ea_tre-1999" TYPE="REFERENCE">Prêtre 1999</LINK>). In particular, the issues spanned the appropriate selection of participants, possibility of cross-over (that is, allowing participants to shift from medical treatment to TMLR), inappropriate blinding of evaluators committed to assess angina, and other features of these studies (<LINK REF="REF-Saririan-2003" TYPE="REFERENCE">Saririan 2003</LINK>; <LINK REF="REF-Sharples-1999" TYPE="REFERENCE">Sharples 1999</LINK>; <LINK REF="REF-Williams-1999" TYPE="REFERENCE">Williams 1999</LINK>; <LINK REF="REF-Williams-2000" TYPE="REFERENCE">Williams 2000</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2015-02-10 05:53:26 +0000" MODIFIED_BY="[Empty name]">
<P>After a thoracotomy, a laser device is placed on the epicardial surface of the left ventricle, creating 10 to 50 small channels from the epicardium to the endocardium (<LINK REF="REF-Mirhoseini-1982" TYPE="REFERENCE">Mirhoseini 1982</LINK>). The mechanism of action remains unknown. Initially, it was thought that the channels provided direct perfusion to the myocardium, but it has been found that the channels close a few days after the procedure. Other mechanisms, such as denervation or neo angiogenesis, have been proposed, but no clear evidence is available (<LINK REF="REF-Lange-1999" TYPE="REFERENCE">Lange 1999</LINK>; <LINK REF="REF-Pr_x00ea_tre-1999" TYPE="REFERENCE">Prêtre 1999</LINK>). The exact mechanism of action of TMLR still remains unknown. Several explanations have been proposed, including placebo effect, direct perfusion, denervation and angiogenesis (<LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-02-25 08:58:42 +0000" MODIFIED_BY="[Empty name]">
<P>This review is an update of a previously published review in <I>The Cochrane Database of Systematic Reviews</I> 2009, Issue 1 (<LINK REF="REF-Briones-2009" TYPE="REFERENCE">Briones 2009</LINK>).</P>
<P>This is an update of a review previously published in 2009. As the use of laser revascularization spread, several technology assessment reports (<LINK REF="REF-Briones-2003" TYPE="REFERENCE">Briones 2003</LINK>; <LINK REF="REF-MSAC-1999" TYPE="REFERENCE">MSAC 1999</LINK>) and one systematic review have been published (<LINK REF="REF-Liao-2005" TYPE="REFERENCE">Liao 2005</LINK>). Due to contradictory results among RCTs on this topic, and the methodological problems found in some studies, it was felt that a more comprehensive systematic review was needed.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-02-25 09:11:39 +0000" MODIFIED_BY="[Empty name]">
<P>This review aims to assess the effects (both benefits and harms) of TMLR versus optimal medical treatment in people with refractory angina who are not candidates for percutaneous coronary angioplasty or coronary artery bypass graft, in alleviating angina severity, reducing mortality and improving ejection fraction.<BR/>
</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-02-25 09:02:46 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-02-25 09:02:46 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-02-10 06:00:04 +0000" MODIFIED_BY="[Empty name]">
<P>Eligible studies were RCTs with a parallel design and a minimum follow-up period of 12 months.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-02-25 09:02:46 +0000" MODIFIED_BY="[Empty name]">
<P>We included studies of adults, 18 years or older, with angina classified as grade III or IV using the Canadian Cardiovascular Society (CCS) angina scale or New York Heart Association (NYHA) anginal class, and who were considered not to be candidates for revascularization using other conventional procedures (coronary artery bypass graft or percutaneous coronary angioplasty). We included studies with participants previously treated with a revascularization procedure, but receiving only the TMLR procedure during the study. We also included studies of participants with a diagnosis of acute coronary syndrome (or unstable angina).<BR/>
</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-02-10 06:06:49 +0000" MODIFIED_BY="[Empty name]">
<P>Transmyocardial laser revascularization performed by thoracotomy using a CO2, YAG-Holmyum or excimer laser, was compared with optimal medical treatment for angina. Studies comparing other laser revascularization techniques, such as percutaneous or adjuvant to other techniques (coronary artery bypass graft or percutaneous coronary angioplasty) were excluded from this review. This is justified by the foreseeable differences in effect, and in order to keep homogeneity. Effectiveness of other techniques is considered for comparison. purposes.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-02-10 23:26:09 +0000" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-02-10 06:07:39 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Improvement of severity of angina as measured by the Canadian Cardiovascular Society (CCS) angina scale or New York Heart Association (NYHA) anginal class.</LI>
<LI>One-year mortality.</LI>
<LI>Early postoperative mortality (deaths in the first month after surgery).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-02-10 23:26:09 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Improvement in exercise tolerance, as measured by the duration of a treadmill exercise test.</LI>
<LI>Health-related quality of life using generic or specific instruments.</LI>
<LI>Myocardial perfusion as assessed by thallium-201 photon emission computed tomography, technetium-99m-labelled sestamibi or a dipyridamol thallium stress test.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-02-10 06:13:47 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2015-02-10 06:09:51 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the following electronic databases on 11 June 2014, without applying any language or date restrictions:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL), 2014, Issue 6.</LI>
<LI>MEDLINE (PubMed) (1946 to Week 1, 2014).</LI>
<LI>EMBASE (Ovid) (1980 to Week 20, 2014).</LI>
</UL>
<P>The search strategies for each database are reported in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> (for the search in 2014) and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> (for the search in 2007).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-02-10 06:13:47 +0000" MODIFIED_BY="[Empty name]">
<P>We checked the reference lists of retrieved articles for additional trials.</P>
<P>We searched ongoing studies in the metaRegister of Controlled Trials database (mRCT) (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>), WHO International Clinical Trials Registry (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en/">www.who.int/ictrp/search/en/</A>) and the National Library of Medicine database, ClinicalTrials.gov (<A HREF="http://clinicaltrials.gov">clinicaltrials.gov</A>). The searching terms were "revascularization AND laser". Other complementary sources were searched, such as reports published by health technology assessment agencies and other systematic reviews in DARE (accessible at <A HREF="http://www.york.ac.uk/inst/crd/crddatabases.htm">www.york.ac.uk/inst/crd/crddatabases.htm</A>).</P>
<P>We also scanned and checked the reference lists of some previous reviews (<LINK REF="REF-Briones-2003" TYPE="REFERENCE">Briones 2003</LINK>; <LINK REF="REF-Liao-2005" TYPE="REFERENCE">Liao 2005</LINK>) summarizing results on TMLR.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-02-23 19:11:14 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2015-02-23 19:11:14 +0000" MODIFIED_BY="[Empty name]">
<P>One author performed literature searches (JRR) in the databases and retrieved all papers fulfilling the inclusion criteria. In a second step, two review authors (EB and JRR) selected those trials to be included in this review, working independently and using the established inclusion criteria. In those articles in which the title or the abstract did not provide enough information to decide on rejection, the review authors obtained a full text copy to evaluate for inclusion. Cases of disagreement about the inclusion or exclusion were decided by consensus after consultation with a third review author (JRL).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-12-04 17:48:43 +0000" MODIFIED_BY="[Empty name]">
<P>A data extraction form was specifically designed for this review; it is available upon request from the authors. It was previously tested for comprehensiveness and reproducibility by using some of the papers located in the search phase. Two authors (EB and JRL) independently performed both quality assessment and data extraction, and disagreement was resolved by consensus. All reported outcomes were taken directly from the studies, and no recalculations were performed.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-12-04 17:48:53 +0000" MODIFIED_BY="[Empty name]">
<P>For this update of the review, judgement of the risk of bias of the included studies has been assessed according to the methods and criteria defined in the last version of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Three authors (EB, JRL and JRR) independently assessed the risk of bias for each study for the following domains: sequence generation, allocation concealment, blinding of participants, personnel and outcome assessment, incomplete outcome data and selective reporting. Any disagreement was resolved by discussion and consensus.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-02-10 07:48:17 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>We report data for dichotomous outcomes as odds ratios (ORs) with 95% confidence intervals (CIs). In cases where an outcome with a zero event was noted, we estimated the Peto OR and 95% CI.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continous data</HEADING>
<P>We used mean differences (i.e. control minus intervention group) for continuous outcomes, estimating differences in the means.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2015-02-11 01:47:34 +0000" MODIFIED_BY="[Empty name]">
<P>We analyzed all dichotomous data by intention-to-treat (ITT). The total number of participants randomly allocated to each treatment group was used to estimate the rate of response in order to compare the treatments. Several studies reported some of their results only graphically, without numerical information. In those cases, no imputation was performed and those results were not included in the analysis. We did not contact the authors of included studies with requests for additional data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-02-10 07:51:17 +0000" MODIFIED_BY="[Empty name]">
<P>We tested pooled data for heterogeneity using Review Manager 5 software via a fixed-effect approach when no significant heterogeneity was found. If heterogeneity could not be explained, the data were pooled using a random effect approach and compared with fixed effect results. In sensitivity analyses, the effects of exclusion of trials for each methodological category were evaluated separately. We carried out a subgroup analysis comparing the results among different angina scales after noting that included studies used different angina severity scales (Canadian Cardiovascular Society (CCS) and New York Heart Association (NYHA)).</P>
</HETEROGENEITY_ASSESSMENT>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-02-25 09:06:21 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-02-25 09:04:00 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-02-10 07:57:19 +0000" MODIFIED_BY="[Empty name]">
<P>The search retrieved 502 references in total: 91 in CENTRAL, 167 in EMBASE, 160 in MEDLINE, and 84 from three clinical trial registers. We excluded four hundred and fifty-five papers after reviewing the title and abstract (generally due to lack of suitability of study design or intervention or duplicate records). We retrieved papers for 47 references for more detailed evaluation and 20 (reporting on 7 studies) references were included in the review (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<P>For this updated version we have not included any additional studies; none of the new studies published from June 2007 fulfilled the inclusion criteria of this review.</P>
<P>Searches in clinical trial registers located 84 references, but among them we did not find any ongoing or future RCT on the topic of this review.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-02-25 09:04:00 +0000" MODIFIED_BY="[Empty name]">
<P>The included papers reported data from seven different studies. In total, 1137 participants were randomized; 559 participants were allocated to the TMLR group. All studies were published in peer reviewed journals. In three studies, the intervention was performed using the Holmiun YAG laser (<LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>; <LINK REF="STD-Burkhoff-1999" TYPE="STUDY">Burkhoff 1999</LINK>; <LINK REF="STD-Jones-1999" TYPE="STUDY">Jones 1999</LINK>), the CO2 laser was used in three studies (<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK>; <LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>; <LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>), and the remaining study used the XeCl excimer laser (<LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>). Technical details of the operative technique were considered to be similar among the studies. The studies showed differences in severity of angina at baseline; in two studies (<LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>; <LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>) a great majority of participants were in Canadian Cardiovascular Society (CCS) class IV. In another two studies (<LINK REF="STD-Burkhoff-1999" TYPE="STUDY">Burkhoff 1999</LINK>; <LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>), the proportion of participants in class IV was around two-thirds, and in the remaining studies, the proportion was less than two-thirds. Two studies (<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK>; <LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>) measured the severity of angina using the New York Heart Association (NYHA) scale instead of the CCS score.</P>
<P>The following exclusion criteria for participants were compiled from the included studies: the need for continued use of intravenous antianginal medication; an inability to undergo the dipyridamole-thallium stress scintigraphy; a non-Q wave myocardial infarction within the two previous weeks or a Q-wave myocardial infarction within the three previous weeks; myocardial infarction in the previous weeks; the need for anticoagulant therapy; the presence of a ventricular mural thrombus; severe arrhythmias; decompensated congestive heart failure; patients with left main coronary artery lesions of greater than 70% without open bypasses to the anterior descending or circumflex arteries; cardiac transplant; lack of informed consent, life expectancy of less than 12 months because of a non-cardiac disorder, such as malignant disease, or those judged to be poor surgical candidates.</P>
<P>Primary outcomes of the selected studies were: exercise test in three studies (<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK>; <LINK REF="STD-Burkhoff-1999" TYPE="STUDY">Burkhoff 1999</LINK>; <LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>) and reduction in angina class in four studies (<LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>; <LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>; <LINK REF="STD-Jones-1999" TYPE="STUDY">Jones 1999</LINK>; <LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>). In all studies, angina relief was defined as a reduction by at least two classes in the CCS or NYHA score. In one study (<LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>), chest pain was also assessed on an 11-point scale, with 0 as no pain and 10 as extreme pain. An exercise test was performed in most studies, though different protocols and outcome measures were used. Outcomes were measured at 12 months in a follow-up visit; all studies also reported some results at different points of time. One study (<LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>) reported results at one month, and all studies except one (<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK>) reported results at six months. Three studies (<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK>; <LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>; <LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>) have also published results of longer follow-up periods, ranging from three to five years.</P>
<P>Five studies (<LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>; <LINK REF="STD-Burkhoff-1999" TYPE="STUDY">Burkhoff 1999</LINK>; <LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>; <LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>; <LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>) reported results on quality of life as measured with these different scales: Duke Activity Index, Seattle Angina Questionnaire (SAQ), MOS-SF36 and EuroQol. Summary data on some variables, such as treadmill exercise mean time, are not reported; therefore, they are not included in the review. In one study (<LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>), a cost-utility analysis was published.</P>
<P>Due to the different characteristics of participants included in the studies, a detailed description is given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> tables; details of outcomes measured as reported in the papers are shown in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-02-10 08:05:08 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded twenty-six studies. The reasons for exclusion are grouped in the following categories: combination with other surgical procedures (<LINK REF="STD-Allen-2000" TYPE="STUDY">Allen 2000</LINK>; <LINK REF="STD-Dowling-2003" TYPE="STUDY">Dowling 2003</LINK>; <LINK REF="STD-Dziuk-2003" TYPE="STUDY">Dziuk 2003</LINK>; <LINK REF="STD-Frazier-2004" TYPE="STUDY">Frazier 2004</LINK>; <LINK REF="STD-Loubani-2003" TYPE="STUDY">Loubani 2003</LINK>); percutaneous transmyocardial laser revascularization (<LINK REF="STD-Dixon-2001" TYPE="STUDY">Dixon 2001</LINK>; <LINK REF="STD-Leon-2005" TYPE="STUDY">Leon 2005</LINK>; <LINK REF="STD-Oesterle-1999" TYPE="STUDY">Oesterle 1999</LINK>; <LINK REF="STD-Oesterle-2000" TYPE="STUDY">Oesterle 2000</LINK>; <LINK REF="STD-Salem-2004" TYPE="STUDY">Salem 2004</LINK>; <LINK REF="STD-Salem-2005" TYPE="STUDY">Salem 2005</LINK>; <LINK REF="STD-Salem-2006" TYPE="STUDY">Salem 2006</LINK>; <LINK REF="STD-Stone-2002" TYPE="STUDY">Stone 2002</LINK>; <LINK REF="STD-Yang-2007" TYPE="STUDY">Yang 2007</LINK>); other treatments (<LINK REF="STD-Appelman-1996" TYPE="STUDY">Appelman 1996</LINK>; <LINK REF="STD-Appelman-1998" TYPE="STUDY">Appelman 1998</LINK>; <LINK REF="STD-Appelman-2000" TYPE="STUDY">Appelman 2000</LINK>; <LINK REF="STD-Kniazeva-1994" TYPE="STUDY">Kniazeva 1994</LINK>; <LINK REF="STD-McNab-2006" TYPE="STUDY">McNab 2006</LINK>; <LINK REF="STD-Vasil_x0027_ev-2003" TYPE="STUDY">Vasil'ev 2003</LINK>); non-comparative studies (<LINK REF="STD-Guleserian-2003" TYPE="STUDY">Guleserian 2003</LINK>; <LINK REF="STD-Milano-1997" TYPE="STUDY">Milano 1997</LINK>); and other reasons, such as three narrative overviews of RCTs (<LINK REF="STD-Horvath_x002c_-2000a" TYPE="STUDY">Horvath, 2000a</LINK>; <LINK REF="STD-Horvath_x002c_-2000b" TYPE="STUDY">Horvath, 2000b</LINK>; <LINK REF="STD-Horvath_x002c_-2002" TYPE="STUDY">Horvath, 2002</LINK>), or comparison of transmyocardial and percutaneous revascularization (<LINK REF="STD-Myers-2002" TYPE="STUDY">Myers 2002</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-02-25 09:04:33 +0000" MODIFIED_BY="[Empty name]">
<P>The risk of bias of the included studies is summarized in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. More detailed information is presented in the 'Risk of bias' tables for each study. Sequence generation for randomisation was considered at low risk of bias in three studies (<LINK REF="STD-Burkhoff-1999" TYPE="STUDY">Burkhoff 1999</LINK>; <LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>; <LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>) and unclear in four studies (<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK>; <LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>; <LINK REF="STD-Jones-1999" TYPE="STUDY">Jones 1999</LINK>; <LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>). In three studies allocation concealment was considered unclear (<LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>; <LINK REF="STD-Jones-1999" TYPE="STUDY">Jones 1999</LINK>; <LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>). Blinding of participants or healthcare personnel was not attempted in most of the studies. As with other surgical procedures, blinding of participants or healthcare providers is not an easy task, but it could be achieved using sham operations and similar procedures (<LINK REF="REF-Bienenfeld-1996" TYPE="REFERENCE">Bienenfeld 1996</LINK>). However, this may raise important ethical issues (<LINK REF="REF-Macklin-1999" TYPE="REFERENCE">Macklin 1999</LINK>). On the other hand, only one study (<LINK REF="STD-Burkhoff-1999" TYPE="STUDY">Burkhoff 1999</LINK>) performed a blinded assessment of a primary outcome, but the appropriateness of blinding was considered uncertain due to inappropriate reporting of data. It is considered that persons responsible for assessing outcomes should be unaware of the assigned intervention in order to avoid detection bias. This is not the case in the studies included, and therefore we considered that performance and detection bias were not adequately prevented in any of the studies.</P>
<P>In two studies (<LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>; <LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>) crossover was allowed, and participants allocated to the control group were offered to undergo TMLR. Intention-to-treat analysis was carried out in both cases. Attrition bias may be present in some studies due to a poor description on deaths and losses to follow-up. In order to have a complete view of the results, we used both intention-to-treat and as-treated results for the analysis of mortality variables.</P>
<P>Two studies (<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK>; <LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>) reported no losses to follow-up and withdrawals. In two studies (<LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>; <LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>), the proportion was lower in the treatment group (4.4% and 4.2%) than in the medication group (10.9% and 6.4%). In one study (<LINK REF="STD-Burkhoff-1999" TYPE="STUDY">Burkhoff 1999</LINK>), the proportion in the revascularization group (9.8%) was higher than in the control group (7.7%). One study (<LINK REF="STD-Jones-1999" TYPE="STUDY">Jones 1999</LINK>) reported an overall proportion of 2.3%, and one study (<LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>) did not report data.</P>
<P>Overall, the main source of bias in included studies was the lack of blinded assessment of subjective outcomes, particularly regarding angina. Secondary outcomes varied, and in most cases (including other measures of cardiac function or disease severity), they were of unknown reliability and no subgroup analysis was attempted.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-02-25 09:06:21 +0000" MODIFIED_BY="[Empty name]">
<P>The studies used different assumptions of primary endpoints. Some trials sought to demonstrate an alleviation of angina without increasing mortality, and others concentrated on functional capacity improvement, as shown by the exercise test. Details of each outcome reported are described below.</P>
<SUBSECTION>
<HEADING LEVEL="3">Angina relief</HEADING>
<P>Changes in angina class were reported in all seven studies; five used the CCS measure (<LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>; <LINK REF="STD-Burkhoff-1999" TYPE="STUDY">Burkhoff 1999</LINK>; <LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>; <LINK REF="STD-Jones-1999" TYPE="STUDY">Jones 1999</LINK>; <LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>) and two used the NYHA measure (<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK>; <LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>). Overall, 43.80% of participants in the treatment group decreased two angina classes as compared with 14.77% in the control group. All studies showed a significant reduction in at least two angina classes, with a wide variation of odds ratios (ORs) ranging from 1.71 (<LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>) to 79.22 (<LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>) and a pooled OR of 4.63 (95% CI 3.43 to 6.25; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The test for heterogeneity was statistically significant (Chi<SUP>2 </SUP>= 34.41, P &lt; 0.0001). The source of heterogeneity may be due to one study, showing results with zero cases in the control group (<LINK REF="STD-Jones-1999" TYPE="STUDY">Jones 1999</LINK>). Studies using the CCS measure showed a lower odds ratio (OR 3.95, 95% CI 2.90 to 5.39) than studies using the NYHA (OR 68.32, 95% CI 7.95 to 587.38).</P>
<P>We performed a subgroup analysis, separating the studies according to the angina scale used under the assumption that they may measure angina in different ways or measure different things. Studies that used the NYHA showed a higher pooled OR of 68.32 (95% CI 7.95 to 587.38) and the test for heterogeneity was not statistically significant. On the contrary, studies using the CCS to test for heterogeneity were still significant and the pooled odds ratio was lower (OR 3.95, 95% CI 2.90 to 5.39).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Mortality</HEADING>
<P>Seven studies reported data on overall mortality, including perioperative and postoperative deaths (<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK>; <LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>; <LINK REF="STD-Burkhoff-1999" TYPE="STUDY">Burkhoff 1999</LINK>; <LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>; <LINK REF="STD-Jones-1999" TYPE="STUDY">Jones 1999</LINK>; <LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>; <LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>). This was done in order to provide a more detailed approach to the participants' survival. The overall mortality rate at one year using intention-to-treat analysis was 12.2% in the TMLR group and 11.9% in the control group. The pooled OR was 1.12 (95% CI 0.77 to 1.63; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) and using as-treated analysis was 1.22 (95% CI 0.81 to 1.83; <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), showing no statistically significant differences in both cases.</P>
<P>Six studies also reported data on early postoperative mortality (deaths after 30 days of intervention) (<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK>; <LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>; <LINK REF="STD-Burkhoff-1999" TYPE="STUDY">Burkhoff 1999</LINK>; <LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>; <LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>; <LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>). Overall, using intention-to-treat analysis, 4.01% of participants died in the TMLR group, ranging from 1.1% to 6.6%, and 3.5% died in the control, showing no statistically significant difference; the pooled OR was 1.19 (95% CI 0.63 to 2.24; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). However, the mortality rate of participants as-treated was 6.8% in the TMLR group and 0.8% in the control group, showing a statistically significant difference; the pooled OR was 3.76 (95% CI 1.63 to 8.66; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). This difference is mainly due to the different mortality in crossover participants, showing the high risk of the procedure under certain circumstances.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Exercise tolerance</HEADING>
<P>Although this outcome was measured in several studies in different ways, only two studies reported data suitable to be pooled (<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK>; <LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>). The variable was the change in exercise duration from basal measurements to 12 months in both groups - treatment and control. The pooled weighted mean difference (WMD) showed an improved, but not statistically significant effect on TMLR participants (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). Additionally, one study (<LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>) reported differences between the groups, but raw data was only shown graphically and therefore not included in the pooled analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>Two studies (<LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>; <LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>) published data obtained by the Seattle Angina Questionnaire; they reported data in three domains. The results were pooled using the difference in the means at 12 months for each domain, assuming that basal values were similar. The physical component of the Seattle Angina Questionnaire was significantly improved among TMLR participants (WMD 13.10; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>), but differences in the other two domains (the frequency of angina (WMD -5.93; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>) and the perceived quality of life (WMD 2.19; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>)) were smaller and not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other outcome measurements</HEADING>
<P>We assessed other outcome measures in the studies, such as myocardial perfusion assessment (thallium-201, photon emission computed tomography, technetium-99m-labelled sestamibi, or a dipiridamol thallium stress test). However, they were not reported appropriately to be pooled and therefore not considered for the purpose of this review. We did not consider other related adverse events such as myocardial infarction, arrhythmias or heart failure in this review, as they were not predefined outcomes in trial designs, and they show a high inconsistency across studies.</P>
<SUBSECTION>
<HEADING LEVEL="4">Long-term results</HEADING>
<P>
<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK> published results after a mean follow-up of five years. Mortality was not different between the two groups (24% and 22%; not significant). Angina improvement was still present after five years (3% versus 24%; P &lt; 0.001).</P>
<P>
<LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK> also reported results after a mean follow-up of five years. Participants in the TMLR group experienced two or more CSS class improvements (42 of 48 (88%)) compared with participants in the control group (16 of 36 (44%)). Survival was higher in the TMLR group than in the control group (65% versus 52%, P &lt; 0.05).</P>
<P>
<LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK> published follow-up data, but only on those participants who underwent TMLR, without publishing data on control participants. In this group, the improvement in angina after five years was very similar to that at one year, with 68% of participants showing a reduction of two or more in angina class. Also the results of the Seattle Angina Questionnaire showed a significant improvement at five years, compared with baseline, for all the components of this scale.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-02-25 09:13:22 +0000" MODIFIED_BY="[Empty name]">
<P>Transmyocardial laser revascularization (TMLR) has been subject to substantial controversy since the first studies were published, due to the contradictory results of efficacy and safety and the lack of explanation about the possible mechanisms of action. This updated systematic review provides a complete picture of the studies, including a new assessment of methodological quality and analysis of all outcomes published. No new trials have been published since previous publication, but risk of bias tables have been completely updated.</P>
<P>In original studies, a significant reduction in angina class was reported, but it was measured using unblinded methods, and a high risk of bias for the assessment of this and other subjective outcomes was found. No evidence of exercise capacity improvement was reported and, similarly, no improvement in survival at 12 months for TMLR participants. However, a statistically significant three-fold increase in 30-day postoperative mortality was found when participants were analyzed as-treated, although the intention-to-treat analysis showed no difference between groups.</P>
<P>All studies recruited participants with medically refractory angina not amenable to other revascularization techniques, who were randomized to TMLR versus medical management. In two trials, crossover was allowed and a substantial proportion of participants received the intervention after randomisation. Although we performed an intention-to-treat analysis, we considered it appropriate to analyse participants in the group that they were actually treated, in order to take into account the risks associated with the intervention. This approach showed a statistically significant higher risk of death in the treated group at 30 days, but not at the 12-month follow-up.</P>
<P>With regards to reduction of the degree of angina, the review shows that TMLR significantly reduced the angina score by at least two classes in the Canadian Cardiovascular Society (CCS) angina scale. Two out of seven of the original studies measured angina severity with the New York Heart Association (NYHA) scale. Although it is different from the CCS angina scale, a subgroup analysis yielded similar results. In this review we consider both scales as having equivalent clinical interpretation and weaknesses due to their subjective conditions.</P>
<P>In both cases, the main endpoint was the degree of improvement in angina (we considered a positive outcome a decrease in two classes at one year). TMLR treated participants had an absolute difference of 29% of positive outcome compared with the control group (43.8% versus 14.8%). It is relevant to note that angina is similar to pain as a subjective measure, and that it was assessed in an unmasked way to both participants and evaluators, and thereby conditioned a high risk of bias (<LINK REF="REF-Bienenfeld-1996" TYPE="REFERENCE">Bienenfeld 1996</LINK>). Blinding could be achieved using sham operations and similar procedures (<LINK REF="REF-Bienenfeld-1996" TYPE="REFERENCE">Bienenfeld 1996</LINK>), but it may raise important ethical issues (<LINK REF="REF-Macklin-1999" TYPE="REFERENCE">Macklin 1999</LINK>). However, it was achieved in interventions performed percutaneously and it is always possible to blind evaluators of outcome measurements (<LINK REF="STD-Leon-2005" TYPE="STUDY">Leon 2005</LINK>).</P>
<P>With regard to exercise tolerance, the review did not show an improvement in effort capacity when pooling the two trials with available data. In the other three trials which observed improvement of exercise capacity, we could not combine the data. It is remarkable that exercise treadmill testing was measured in each trial in a different way and in some trials in a non-standardized way; this hindered the comparison of exercise performance. In addition, an unblinded assessment of the exercise test also hampered the credibility of the results.</P>
<P>Another interesting outcome is health related quality of life (HRQoL), where an improvement in physical well-being dimension was found in two studies as measured by the Seattle Angina Questionnaire. This result is consistent with the improvement in angina class scores, given that the reasons as to why the participants reported HRQoL deficits directly correlated to recurrent angina. This concordance between physical quality of life and angina improvement is also seen with other long-term follow-up studies of revascularization procedures (coronary artery bypass graft and percutaneous coronary intervention). No improvement was found in the other two domains (frequency of angina and perceived quality of life) from the available pooled data. Ideally, longitudinal assessment to evaluate changes over time in HRQoL outcomes with both general and disease-specific tools is desirable, but this was not available in the original studies.</P>
<P>A key issue is the lack of correlation of the subjective reduction of symptoms detected with a failure to demonstrate improvement in perfusion. The studies reveal that the overall number of sites with reversible perfusion defects did not significantly differ between the TMLR and medical management groups, even with an unblinded assessment in the trials. This raises the issue explaining the mechanism of how TMLR achieves its effects when a placebo effect could not be discarded.</P>
<P>A difficulty in the interpretation of the results is the diversity of inclusion criteria in the studies. Although some relevant variables such as the type of laser, severity of angina and concomitant medical therapy were not identical across trials, and formal tests for heterogeneity had a low power, the pool of studies is consistent in their relative effect sizes. Selection of participants and medical treatment are two clinical issues of interest. It was assumed in the studies that participants received optimal medical treatment. However, it has been acknowledged that half of the participants could have been stabilized with intensification of antianginal therapy alone (<LINK REF="REF-N_x00e4_gele-1998" TYPE="REFERENCE">Nägele 1998</LINK>). Some criticism has also been made concerning the inclusion criteria in trials with regards to the high proportion of participants not amenable for coronary artery bypass graft or to optimized medical treatment.</P>
<P>Also, the size and duration of the effect make it difficult to exclusively attribute it to unmasked assessment, but the available evidence is not strong enough to draw firm conclusions. Another suggested interpretation is that the long-term improvement of angina may be due to a differential selection of participants, where those with more severe angina would have a higher mortality after the intervention, thereby making the survivors appear symptomatically better. In a previous review, this effect was assessed in a sensitivity analysis by including all deaths as treatment failures. These results were not substantively different from the primary analysis, suggesting this does not explain the observed reductions in angina class after TMLR (<LINK REF="REF-Liao-2005" TYPE="REFERENCE">Liao 2005</LINK>).</P>
<P>The problem of non-adherence to the allocated treatment in randomized trials of cardiac surgery has been reported in other large scale studies (<LINK REF="REF-Peduzzi-1991" TYPE="REFERENCE">Peduzzi 1991</LINK>). Alternative methods of analysis have been proposed: censoring crossovers, excluding them completely, transferring participants from one treatment group to another, or counting crossovers as if they had been allocated to the treatment ultimately received. Comparisons according to intention-to-treat is considered the most valid approach to compare treatments, producing unbiased estimates of effect measures. Notwithstanding, it is also interesting to get information about the harms directly associated with the surgical procedure, as deaths occurring in the days after the surgery, regardless the group originally assigned in the trials. When data were analyzed in this way, we observed a higher early mortality among those receiving revascularization, mainly due to the different mortality in crossover participants, showing the high risk of the procedure under certain circumstances.</P>
<P>However, the one-year mortality odds ratio was similar both in the intention-to-treat and as-treated analysis, and therefore could be interpreted as revascularization having no effect in changing the prognosis of these participants.</P>
<P>It is interesting to note that other therapeutic alternatives not addressed in this review have also been attempted. In the last few years, various clinical trials have published efficacy tests of percutaneous laser myocardial revascularization versus a sham procedure (<LINK REF="STD-Leon-2005" TYPE="STUDY">Leon 2005</LINK>) and versus spinal cord stimulation (<LINK REF="STD-McNab-2006" TYPE="STUDY">McNab 2006</LINK>); however, no comparisons with TMLR have been found. Interestingly, one trial (<LINK REF="STD-Leon-2005" TYPE="STUDY">Leon 2005</LINK>) is the only known randomized controlled trial (RCT) designed to avoid the placebo effect that was carried out with double-blinding (comparison with a sham procedure and evaluator-blinded assessment of outcomes). No statistically significant difference was found in exercise duration or angina class.</P>
<P>For the interpretation of results, it is important to consider which assumptions are made concerning the ultimate goal of this treatment. For some authors, TMLR is aimed at alleviating the symptoms of myocardial ischaemia without compromising survival or cardiac function for end-stage participants with no other options available. Therefore, it can be considered an alternative procedure for alleviating angina, but with some potential risks, and the goal of the intervention may differ from what had been originally proposed. It could also be argued that other alternatives for this end-stage of disease have not been fully considered (<LINK REF="REF-Kim-2002" TYPE="REFERENCE">Kim 2002</LINK>). Also, other revascularization alternatives, such as minimally invasive surgery and drug eluting stents, have improved over time and have not been compared with TMLR. A key issue is to clarify the criteria for participant selection and information according to published factors related to increased perioperative mortality (<LINK REF="REF-Peterson-2003" TYPE="REFERENCE">Peterson 2003</LINK>).</P>
<P>After publication of the first version of this review, another systematic review was published, including both transmyocardial and percutaneous laser revascularization (<LINK REF="REF-Campbell-2008" TYPE="REFERENCE">Campbell 2008</LINK>). This review was the evidence base for two guidance documents, published by the National Institute for Health and Clinical Excelence (NICE) (<LINK REF="REF-Schofield-2010" TYPE="REFERENCE">Schofield 2010</LINK>). With regards to TMLR, it included comparisons with other interventions, such as adjunct coronary artery bypass graft (two trials) and sympathectomy (one trial). Its findings and conclusions are fully concordant with this review and reinforce the placebo effect explanation for angina reduction. The review also highlights the importance of blinding the assessment of subjective outcomes, using sham operations or other procedures. It could be achieved in percutaneous interventions and no effect was found in improvement of angina (<LINK REF="REF-Campbell-2008" TYPE="REFERENCE">Campbell 2008</LINK>; <LINK REF="STD-Leon-2005" TYPE="STUDY">Leon 2005</LINK>).</P>
<P>No new trials on TMLR have been published in the last ten years, and it is very unlikely that new research is being undertaken in this field. The procedure is becoming outdated and it is very unlikely that current conclusions will change.</P>
<P>Currently, different research alternatives for people suffering from refractory angina are being carried out. On the one hand, proposals for a better classification of this group of people have been made, leading to a more targeted treatment, including better co-ordination of multidisciplinary teams (<LINK REF="REF-Jolicoeur-2012" TYPE="REFERENCE">Jolicoeur 2012</LINK>). On the other hand, cell therapy has shown promising results in this and similar populations (<LINK REF="REF-Clifford-2012" TYPE="REFERENCE">Clifford 2012</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-02-25 09:09:06 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-02-11 00:35:40 +0000" MODIFIED_BY="[Empty name]">
<P>This updated review shows that risks associated with transmyocardial laser revascularization (TMLR) outweigh the potential clinical benefits. The observed improvement in angina is subject to high risk of bias and the effect disappears when assessments have been performed blindly in similar procedures. No differences were found in survival but a significant increase in postoperative mortality and other evidence on safety suggests that the procedure may pose unacceptable risks. Overall, the quality of the evidence is considered to be low, mainly due to the high risk of bias in the assessment of subjective outcomes in all studies.</P>
<P>On the other hand, TMLR is becoming an obsolete technology. No new trials on TMLR have been carried out in the last ten years and it is very unlikely that new research is being undertaken in this field and that current conclusions will change.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-02-25 09:09:06 +0000" MODIFIED_BY="[Empty name]">
<P>This review reinforces the idea that lack of blinding is one of the main pitfalls in studies assessing subjective outcomes, such as angina or quality of life. Future studies in the field of refractory angina should be better designed, with appropriate blinding of participants, healthcare providers and researchers, and a more precise definition of refractory angina.</P>
<P>Research on new technologies and improvements in service organization should be encouraged in this field, particularly those focusing on cell therapy and multidisciplinary teams' interventions. Methodological issues, such as those considered in this review should be taken into account.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-02-11 00:40:05 +0000" MODIFIED_BY="[Empty name]">
<P>This review is based partly on a research project funded by Instituto Carlos III - Fondo de Investigaciones Sanitarias, Ministry of Health (SPAIN) and research developed at the Andalusian Agency for Health Technology Assessment.<BR/>The Iberoamerican Cochrane Center has kindly provided methodological support and help with Review Manager software.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-02-11 00:44:46 +0000" MODIFIED_BY="[Empty name]">
<P>Eduardo Briones (EB): previous work, conceived the study, co-ordinated the preparation of the protocol, read and selected abstracts and papers, interpreted results, and drafted the review.</P>
<P>Juan Ramon Lacalle (JRL): developed and performed the search strategy and data collection, preparation of the protocol, analyzed data, and contributed to drafting the review.</P>
<P>Ignacio Marin-Leon (IM): previous work, conceived the study, checked the search results, critically revised the manuscript, and provided a clinical and policy perspective.</P>
<P>José-Ramón Rueda (JRR): updated the searches and extracted data for assessment of risks of bias, and contributed to drafting the update of the review.</P>
<P>All authors approved the final version.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-02-25 09:24:31 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-02-25 09:24:31 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-02-25 09:23:10 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aaberge-2000" MODIFIED="2015-02-10 04:02:06 +0000" MODIFIED_BY="[Empty name]" NAME="Aaberge 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-02-10 04:02:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aaberge L, Askhus S, Nordstrand K, Abdelnoor M, Ihlen H, Forfang K</AU>
<TI>Myocardial performance after transmyocardial revascularization with CO(2) laser. A dobutamine stress echocardiographic study</TI>
<SO>European Journal of Echocardiography</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>3</NO>
<PG>187-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 10:32:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aaberge L, Nordstrand K, Dragsund M, Saatvedt K, Endresen K, Golf S, et al</AU>
<TI>Transmyocardial revascularization with CO2 laser in patients with refractory angina pectoris. Clinical results from the Norwegian Randomized Trial</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2000</YR>
<VL>35</VL>
<PG>1170-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aaberge L, Rootwelt K, Blomhoff S, Saatvedt K, Abdelnoor M, Forfang K</AU>
<TI>Continued symptomatic improvement three to five years after transmyocardial laser revascularization with CO(2) laser: a late clinical follow-up of the Norwegian Randomized trial with transmyocardial laser revascularization</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2002</YR>
<VL>39</VL>
<PG>1588-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 08:55:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Aaberge L, Rootwelt K, Smith HJ, Nordstrand K, Forfang K</AU>
<TI>Effects of transmyocardial revascularization on myocardial perfusion and systolic function assessed by nuclear and magnetic resonance imaging methods</TI>
<SO>Scandinavian Cardiovascular Journal</SO>
<YR>2001</YR>
<VL>35</VL>
<PG>8-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-1999" MODIFIED="2008-10-13 10:33:39 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-10-13 10:33:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen KB, Dowling RD, Angell WW, Gangahar DM, Fudge TL, Richenbacher W, et al</AU>
<TI>Transmyocardial laser revascularization: 5 years follow-up of a prospective, randomized trial</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2004</YR>
<VL>77</VL>
<PG>1228-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 10:33:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Allen KB, Dowling RD, Fudge TL, Schoettle P, Sleinger SL, Gangahar DM, et al</AU>
<TI>Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<PG>1029-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burkhoff-1999" MODIFIED="2014-06-27 10:55:57 +0100" MODIFIED_BY="[Empty name]" NAME="Burkhoff 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-06-27 10:55:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burkhoff D, Schmidt S, Schulman SP, Myers J, Resar J, Becker LC, et al</AU>
<TI>Transmyocardial laser revascularization compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomized trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>885-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frazier-1999" MODIFIED="2015-02-11 01:56:47 +0000" MODIFIED_BY="[Empty name]" NAME="Frazier 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-02-10 04:03:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Frazier OH, March RJ, Horvath KA; Transmyocardial Carbon Dioxide Laser Revascularization Group</AU>
<TI>Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<PG>1021-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-10 04:00:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hovarth KA, Aranki SF, Cohn LH, March RJ, Frazier OH, Kadipasaoglu KA, et al</AU>
<TI>Sustained angina relief 5 years after transmyocardial laser revascularization with a CO(2) laser</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>104</VL>
<NO>12 Suppl 1</NO>
<PG>I81-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 08:58:48 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Preliminary analyses using 'as treated' approach, not intention-to-treat&lt;/p&gt;" NOTES_MODIFIED="2008-10-13 08:58:48 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>March RJ</AU>
<TI>Transmyocardial laser revascularization with the CO2 laser: one year results of a randomized, controlled trial</TI>
<SO>Seminars in Thoracic and Cardiovascular Surgery</SO>
<YR>1999</YR>
<VL>11</VL>
<NO>1</NO>
<PG>12-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-11 01:56:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spertus JA, Jones PG, Coen M, Garg M , Bliven B, O'Keefe J, et al</AU>
<TI>Transmyocardial CO2 laser revascularization improves symptoms, function and quality of life: 12-month results from a randomized controlled trial</TI>
<SO>American Journal of Medicine</SO>
<YR>2001</YR>
<VL>111</VL>
<PG>341-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1999" MODIFIED="2015-02-11 01:58:59 +0000" MODIFIED_BY="[Empty name]" NAME="Jones 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-02-11 01:58:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones JW, Schmidt SE, Richman BW, Miller CC, Sapire KJ, Burkhoff D, et al</AU>
<TI>Holmium: YAG laser transmyocardial revascularization relieves angina and improves functional status</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1999</YR>
<VL>67</VL>
<PG>1596-1602</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schofield-1999" MODIFIED="2015-02-25 09:23:10 +0000" MODIFIED_BY="[Empty name]" NAME="Schofield 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-10-13 10:35:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burns SM, Brown S, White CA, Tait S, Sharples L, Schofield PM</AU>
<TI>Quantitative analysis of myocardial perfusion changes with transmyocardial laser revascularization</TI>
<SO>American Journal of Cardiology</SO>
<YR>2001</YR>
<VL>87</VL>
<NO>7</NO>
<PG>861-7</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:00:32 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:00:32 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00372857"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 09:01:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Caine N, Tait S, Campbell H, Buxton M, Sharples LD, Schofield PM, et al</AU>
<TI>The UK trial of transmyocardial laser revascularisation (TMLR): cost effectiveness</TI>
<SO>15th Annual Meeting of the International Society of Technology Assessment in Health Care; 1999 Jun 20-23</SO>
<YR>1999</YR>
<PG>122</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 10:35:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campbell HE, Tait S, Buxton MJ, Sharples LD, Caine N, Schofield PM, et al</AU>
<TI>A UK trial-based cost-utility analysis of transmyocardial laser revascularization compared to continued medical therapy for treatment of refractory angina pectoris</TI>
<SO>European Journal of Cardio-Thoracic Surgery</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>312-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 11:03:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campbell HE, Tait S, Sharples LD, Caine N, Gray TJ, Schofield PM, et al</AU>
<TI>Trial-based cost-utility comparison of percutaneous myocardial laser revascularisation and continued medical therapy for treatment of refractory angina pectoris</TI>
<SO>European Journal of Health Economics</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>4</NO>
<PG>288-97</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:07:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:07:39 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00552367"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 11:03:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schofield PM, Sharples LD, Caine N, Burns S, Tait S, Wistow, T et al</AU>
<TI>Transmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<PG>519-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-02-25 09:23:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tait S, Caine N, Batas D, Sharples LD, Buxton M, Burns S, et al</AU>
<TI>The UK trial of transmyocardial laser revascularisation (TMLR): health related quality of life (HRQOL) [abstract]</TI>
<SO>15th Annual Meeting of the International Society of Technology Assessment in Health Care; 1999 Jun 20-23</SO>
<YR>1999</YR>
<PG>62</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:07:29 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:07:29 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00476490"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Sloot-2004" MODIFIED="2015-02-10 04:04:29 +0000" MODIFIED_BY="[Empty name]" NAME="van der Sloot 2004" YEAR="2003">
<REFERENCE MODIFIED="2015-02-10 04:04:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huikeshoven M, van der Sloot JAP, Tukkie R, van Gemert MJC, Tijssen JGP, Beek JF</AU>
<TI>Improved quality of life after XeCl excimer transmyocardial laser revascularization: results of a randomized trial</TI>
<SO>Lasers in Surgery and Medicine</SO>
<YR>2003</YR>
<VL>33</VL>
<PG>1-7</PG>
<IDENTIFIERS MODIFIED="2008-10-13 11:04:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 11:04:39 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/lsm.10189"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-13 11:04:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Sloot JAP, Huikeshoven M, Tukkie R, Verbene HJ, van der Meulen J, van Eck-Smit BLF, et al</AU>
<TI>Transmyocardial revascularization using an XeCl excimer laser: Results of a randomized trial</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2004</YR>
<VL>78</VL>
<NO>3</NO>
<PG>875-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-02-25 09:24:31 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-2000" MODIFIED="2015-02-10 04:05:06 +0000" MODIFIED_BY="[Empty name]" NAME="Allen 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-02-10 04:05:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen KB, Dowling RD, DelRossi AJ, Realyvasques F, Lefrak EA, Pfeffer TA, et al</AU>
<TI>Transmyocardial laser revascularization combined with coronary artery bypass grafting: a multicenter, blinded, prospective, randomized, controlled trial</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2000</YR>
<VL>119</VL>
<NO>3</NO>
<PG>540-9</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:36:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:36:01 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00275669"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Appelman-1996" MODIFIED="2015-02-10 04:05:10 +0000" MODIFIED_BY="[Empty name]" NAME="Appelman 1996" YEAR="1996">
<REFERENCE MODIFIED="2015-02-10 04:05:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Appelman YE, Piek JJ, Strikwerda S, Tijssen JG, de Feyter PJ, David GK, et al</AU>
<TI>Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<NO>8994</NO>
<PG>79-84</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:36:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:36:42 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00122402"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Appelman-1998" MODIFIED="2008-10-13 09:37:23 +0100" MODIFIED_BY="[Empty name]" NAME="Appelman 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-10-13 09:37:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Appelman YE, Piek JJ, Redekop WK, de Feyter PJ, Koolen JJ, David GK, et al</AU>
<TI>Clinical events following excimer laser angioplasty or balloon angioplasty for complex coronary lesions: subanalysis of a randomised trial</TI>
<SO>Heart (British Cardiac Society)</SO>
<YR>1998</YR>
<VL>79</VL>
<NO>1</NO>
<PG>34-8</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:37:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:37:23 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00148577"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Appelman-2000" MODIFIED="2015-02-10 04:05:30 +0000" MODIFIED_BY="[Empty name]" NAME="Appelman 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-02-10 04:05:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Appelman YE, Piek JJ, van der Wall EE, Redekop WK, van Royen EA, Fioretti PM, et al</AU>
<TI>Evaluation of the long-term functional outcome assessed by myocardial perfusion scintigraphy following excimer laser angioplasty compared to balloon angioplasty in longer coronary lesions</TI>
<SO>International Journal of Cardiac Imaging</SO>
<YR>2000</YR>
<VL>16</VL>
<NO>4</NO>
<PG>267-77</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:38:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:38:25 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00327681"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dixon-2001" MODIFIED="2008-10-13 13:30:00 +0100" MODIFIED_BY="[Empty name]" NAME="Dixon 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-10-13 13:30:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dixon SR, Schreiber TL, Rabah M, Lee DT, Kelco KL, O'Neill WW</AU>
<TI>Immediate effect of percutaneous myocardial laser revascularization on hemodynamics and left ventricular systolic function in severe angina pectoris</TI>
<SO>American Journal of Cardiology</SO>
<YR>2001</YR>
<VL>87</VL>
<NO>5</NO>
<PG>516-9</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:38:31 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:38:31 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00328342"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dowling-2003" MODIFIED="2015-02-10 04:05:40 +0000" MODIFIED_BY="[Empty name]" NAME="Dowling 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-02-10 04:05:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dowling R, Thielmeier K, Ghaly A, Barber D, Boice T, Dine A</AU>
<TI>Improved pain control after cardiac surgery: results of a randomized, double-blind, clinical trial</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2003</YR>
<VL>126</VL>
<NO>5</NO>
<PG>1271-8</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:40:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:40:55 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00459447"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dziuk-2003" MODIFIED="2015-02-10 04:05:47 +0000" MODIFIED_BY="[Empty name]" NAME="Dziuk 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-02-10 04:05:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dziuk M, el-Deeb H, Britton KE, Edmondson SJ, Piechota W, Cholewa M</AU>
<TI>Clinical outcome of patients after transmyocardial laser revascularization alone and combined with coronary artery bypass grafting</TI>
<TO>Kliniczna ocena efektu przezsercowej rewaskularyzacji laserowej polaczonej lub niepolaczonej z pomostowaniem aortalno-wiencowym</TO>
<SO>Polski Merkuriusz Lekarski</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>90</NO>
<PG>534-6</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:39:10 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:39:10 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00559730"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frazier-2004" MODIFIED="2008-10-13 09:40:05 +0100" MODIFIED_BY="[Empty name]" NAME="Frazier 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-13 09:40:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frazier OH, Tuzun E, Eichstadt H, Boyce SW, Lansing AM, March RJ, et al</AU>
<TI>Transmyocardial laser revascularization as an adjunct to coronary artery bypass grafting: a randomized, multicenter study with 4-year follow-up</TI>
<SO>Texas Heart Institute Journal</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>3</NO>
<PG>231-9</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:39:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:39:51 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00492808"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guleserian-2003" MODIFIED="2015-02-10 04:06:12 +0000" MODIFIED_BY="[Empty name]" NAME="Guleserian 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-02-10 04:06:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guleserian KJ, Maniar HS, Camillo CJ, Bailey MS, Damiano RJ, Moon MR</AU>
<TI>Quality of life and survival after transmyocardial laser revascularization with the holmium: YAG laser</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2003</YR>
<VL>75</VL>
<NO>6</NO>
<PG>1842-7; discussion 1847-8</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:40:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:40:18 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00558872"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horvath_x002c_-2000a" MODIFIED="2015-02-10 04:06:20 +0000" MODIFIED_BY="[Empty name]" NAME="Horvath, 2000a" YEAR="2000">
<REFERENCE MODIFIED="2015-02-10 04:06:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horvath KA</AU>
<TI>Results of clinical trials of transmyocardial laser revascularization versus medical management for end-stage coronary disease</TI>
<SO>Journal of Clinical Laser Medicine and Surgery</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>5</NO>
<PG>247-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horvath_x002c_-2000b" MODIFIED="2008-10-13 09:41:31 +0100" MODIFIED_BY="[Empty name]" NAME="Horvath, 2000b" YEAR="2000">
<REFERENCE MODIFIED="2008-10-13 09:41:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horvath KA</AU>
<TI>Transmyocardial laser revascularization in the treatment of myocardial ischemia</TI>
<SO>Journal of Cardiac Surgery</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>4</NO>
<PG>271-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horvath_x002c_-2002" MODIFIED="2008-10-13 09:41:45 +0100" MODIFIED_BY="[Empty name]" NAME="Horvath, 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-10-13 09:41:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horvath KA</AU>
<TI>Results of prospective randomized controlled trials of transmyocardial laser revascularization</TI>
<SO>Heart Surgery Forum</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>1</NO>
<PG>33-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horvath_x002c_-2008" MODIFIED="2015-02-10 04:06:54 +0000" MODIFIED_BY="[Empty name]" NAME="Horvath, 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-02-10 04:06:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horvath KA</AU>
<TI>Transmyocardial laser revascularization</TI>
<SO>Journal of Cardiac Surgery</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>3</NO>
<PG>266-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kniazeva-1994" MODIFIED="2015-02-25 09:23:57 +0000" MODIFIED_BY="[Empty name]" NAME="Kniazeva 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-02-25 09:23:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kniazeva TA, Nagapet'ian VK</AU>
<TI>The use of infrared laser radiation in the rehabilitation of IHD patients after the surgical revascularization of the myocardium</TI>
<TO>Ispol'zovanie infrakrasnogo lazernogo izlucheniia v reabilitatsii bol'nykh IBS posle khirurgicheskoi revaskuliarizatsii miokarda</TO>
<SO>Voprosy Kurortologii, Fizioterapii, i Lechebnoi Fizicheskoi Kultury</SO>
<YR>1994</YR>
<VL>Nov-Dec</VL>
<NO>6</NO>
<PG>10-2</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:42:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:42:54 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00114479"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leon-2005" MODIFIED="2015-02-10 04:07:11 +0000" MODIFIED_BY="[Empty name]" NAME="Leon 2005" YEAR="2005">
<REFERENCE MODIFIED="2015-02-10 04:07:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leon MB, Kornowski R, Downey WE, Weisz G, Baim DS, Bonow RO, et al</AU>
<TI>A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>10</NO>
<PG>1812-9</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:43:06 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:43:06 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00531924"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loubani-2003" MODIFIED="2008-10-13 09:43:41 +0100" MODIFIED_BY="[Empty name]" NAME="Loubani 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-10-13 09:43:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loubani M, Chin D, Leverment JN, Galiñanes M</AU>
<TI>Mid-term results of combined transmyocardial laser revascularization and coronary artery bypass</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>2003</YR>
<VL>76</VL>
<NO>4</NO>
<PG>1163-6</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:43:28 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:43:28 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00458111"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McNab-2006" MODIFIED="2008-10-13 09:44:21 +0100" MODIFIED_BY="[Empty name]" NAME="McNab 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-10-13 09:44:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McNab D, Khan SN, Sharples LD, Ryan JY, Freeman C, Caine N, et al</AU>
<TI>An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial</TI>
<SO>European Heart Journal</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>9</NO>
<PG>1048-53</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:44:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:44:21 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00563544"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milano-1997" MODIFIED="2008-10-13 11:10:59 +0100" MODIFIED_BY="[Empty name]" NAME="Milano 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-10-13 11:10:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Milano, Carlo AD</AU>
<TI>Transmyocardial revascularization with a holmium laser: preliminary results</TI>
<TO>Rivascolarizzazione transmiocardica con laser ad olmio: risultati preliminari</TO>
<SO>Giornale Italiano Di Cardiologia</SO>
<YR>1997</YR>
<VL>27</VL>
<NO>10</NO>
<PG>1011-8</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:46:17 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:46:17 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00338266"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myers-2002" MODIFIED="2008-10-13 09:47:50 +0100" MODIFIED_BY="[Empty name]" NAME="Myers 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-10-13 09:47:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myers J, Oesterle SN, Jones J, Burkhoff D</AU>
<TI>Do transmyocardial and percutaneous laser revascularization induce silent ischemia? An assessment by exercise testing</TI>
<SO>American Heart Journal</SO>
<YR>2002</YR>
<VL>143</VL>
<NO>6</NO>
<PG>1052-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oesterle-1999" MODIFIED="2008-10-13 09:49:40 +0100" MODIFIED_BY="[Empty name]" NAME="Oesterle 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-10-13 09:49:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oesterle SN</AU>
<TI>Laser percutaneous myocardial revascularization</TI>
<SO>American Journal of Cardiology</SO>
<YR>1999</YR>
<VL>83</VL>
<NO>4 A</NO>
<PG>46B-52B</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:49:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:49:40 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00413614"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oesterle-2000" MODIFIED="2008-10-13 09:50:12 +0100" MODIFIED_BY="[Empty name]" NAME="Oesterle 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-10-13 09:50:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oesterle SN, Sanborn TA, Ali N, Resar J, Ramee SR, Heuser R, et al</AU>
<TI>Percutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomised trial. Potential Class Improvement From Intramyocardial Channels</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<NO>9243</NO>
<PG>1705-10</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:50:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:50:12 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00331210"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salem-2004" MODIFIED="2008-10-13 09:50:28 +0100" MODIFIED_BY="[Empty name]" NAME="Salem 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-13 09:50:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salem M, Rotevatn S, Stavnes S, Brekke M, Vollset SE, Nordrehaug JE</AU>
<TI>Usefulness and safety of percutaneous myocardial laser revascularization for refractory angina pectoris</TI>
<SO>American Journal of Cardiology</SO>
<YR>2004</YR>
<VL>93</VL>
<NO>9</NO>
<PG>1086-91</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:50:19 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:50:19 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00469504"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salem-2005" MODIFIED="2008-10-13 09:51:15 +0100" MODIFIED_BY="[Empty name]" NAME="Salem 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-10-13 09:51:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salem M, Rotevatn S, Stavnes S, Brekke M, Pettersen R, Kuiper K, et al</AU>
<TI>Release of cardiac biochemical markers after percutaneous myocardial laser or sham procedures</TI>
<SO>International Journal of Cardiology</SO>
<YR>2005</YR>
<VL>104</VL>
<NO>2</NO>
<PG>144-51</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:51:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:51:02 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00552248"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salem-2006" MODIFIED="2008-10-13 09:51:27 +0100" MODIFIED_BY="[Empty name]" NAME="Salem 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-10-13 09:51:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salem M, Rotevatn S, Nordrehaug JE</AU>
<TI>Long-term results following percutaneous myocardial laser therapy</TI>
<SO>Coronary artery disease</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>4</NO>
<PG>385-90</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:51:26 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:51:26 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00565446"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stone-2002" MODIFIED="2015-02-11 02:00:53 +0000" MODIFIED_BY="[Empty name]" NAME="Stone 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-02-11 02:00:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stone GW, Teirstein PS, Rubenstein R, Schmidt D, Whitlow PL, Kosinski EJ, et al</AU>
<TI>A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecognizable chronic total occlusions</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2002</YR>
<VL>39</VL>
<NO>10</NO>
<PG>1581-7</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:51:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:51:47 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00380195"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vasil_x0027_ev-2003" MODIFIED="2015-02-25 09:24:31 +0000" MODIFIED_BY="[Empty name]" NAME="Vasil'ev 2003" YEAR="2003">
<REFERENCE MODIFIED="2015-02-25 09:24:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vasil'ev AP, Strel'tsova NN, Senatorov IuN</AU>
<TI>Efficacy of laser therapy in patients with ischemic heart disease</TI>
<TO>Effektivnost' lazeroterapii bol'nykh ishemicheskoi bolezn'iu serdtsa</TO>
<SO>Voprosy Kurortologii, Fizioterapii i Lechebnoi Fizicheskoi Kultury</SO>
<YR>2003</YR>
<VL>Jul-Aug</VL>
<NO>4</NO>
<PG>10-3</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:52:16 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:52:16 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00457587"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2007" MODIFIED="2015-02-10 04:08:30 +0000" MODIFIED_BY="[Empty name]" NAME="Yang 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-02-10 04:08:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang SS, Li WM, Yin LL, Li Y, Fan Y, Han W, et al</AU>
<TI>Chronic effects of percutaneous transmyocardial laser revascularization in patients with refractory angina</TI>
<SO>Zhonghua Xin Xue Guan Bing Za Zhi</SO>
<YR>2007</YR>
<VL>35</VL>
<NO>1</NO>
<PG>51-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-06-19 11:24:39 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-02-10 04:19:46 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-02-10 04:19:46 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bienenfeld-1996" MODIFIED="2008-10-13 09:54:39 +0100" MODIFIED_BY="[Empty name]" NAME="Bienenfeld 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bienenfeld L, Frishman W, Glasser SP</AU>
<TI>The placebo effect in cardiovascular disease</TI>
<SO>American Heart Journal</SO>
<YR>1996</YR>
<VL>132</VL>
<NO>6</NO>
<PG>1207-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borras-2012" MODIFIED="2015-02-10 04:10:36 +0000" MODIFIED_BY="[Empty name]" NAME="Borras 2012" TYPE="JOURNAL_ARTICLE">
<AU>Borrás X, Garcia-Moll X, Gomez-Doblas JJ, Zapata A, Artigas R; AVANCE study researchers</AU>
<TI>Stable angina in Spain and its impact on quality of life. The AVANCE registry</TI>
<SO>Revista Espanol de Cardiologia (English Edition)</SO>
<YR>2012</YR>
<VL>65</VL>
<NO>8</NO>
<PG>734-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Briones-2003" MODIFIED="2008-10-13 11:13:58 +0100" MODIFIED_BY="[Empty name]" NAME="Briones 2003" TYPE="BOOK">
<AU>Briones E, Rodriguez FJ</AU>
<SO>Eficacia, seguridad y eficiencia de la revascularización transmiocárdica con láser [Efficacy, security and efficiency of transmyocardial laser revascularization]</SO>
<YR>2003</YR>
<PB>Ministerio de Sanidad y Consumo</PB>
<CY>Madrid</CY>
<IDENTIFIERS MODIFIED="2008-10-13 09:56:32 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:56:32 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISBN 84-760-664-2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Burkhoff-2001" NAME="Burkhoff 2001" TYPE="JOURNAL_ARTICLE">
<AU>Burkhoff D, Jones JW, Becker LC</AU>
<TI>Variability of myocardial perfusion defects by thallium 201 scintigraphy in patients with coronary artery disease not amenable to angioplasty or bypass surgery</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2001</YR>
<VL>38</VL>
<PG>1033-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caine-1998" MODIFIED="2008-10-13 09:57:17 +0100" MODIFIED_BY="[Empty name]" NAME="Caine 1998" TYPE="JOURNAL_ARTICLE">
<AU>Caine N, Schofield PM, Wallwork J, Sharples LD</AU>
<TI>British trial of transmyocardial revascularisation is continuing</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<NO>7129</NO>
<PG>474-5</PG>
<IDENTIFIERS MODIFIED="2008-10-13 09:57:17 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 09:57:17 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00258677"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Campbell-2008" MODIFIED="2014-06-13 11:05:57 +0100" MODIFIED_BY="[Empty name]" NAME="Campbell 2008" TYPE="OTHER">
<AU>Campbell F, Messina J, FitzGerald P, Cantrell A, Czoski-Murray C</AU>
<TI>Systematic review of the efficacy and safety of transmyocardial and percutaneous laser revascularisation for refractory angina pectoris</TI>
<SO>Review body for interventional procedures (ScHARR). Shefield</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clifford-2012" MODIFIED="2015-02-10 04:11:25 +0000" MODIFIED_BY="[Empty name]" NAME="Clifford 2012" TYPE="COCHRANE_REVIEW">
<AU>Clifford DM, Fisher SA, Brunskill SJ, DoreeC, MathurA, Watt S, et al</AU>
<TI>Stem cell treatment for acute myocardial infarction</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2014-06-19 11:28:17 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-19 10:48:49 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006536.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cooley-1996" MODIFIED="2008-10-13 09:57:35 +0100" MODIFIED_BY="[Empty name]" NAME="Cooley 1996" TYPE="JOURNAL_ARTICLE">
<AU>Cooley DA, Frazier OH, Kadipasaoglu KA, Lindenmeir MH, Pehlivanoglu S, Kolff JW, et al</AU>
<TI>Transmyocardial laser revascularization: clinical experience with twelve-month follow-up</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1996</YR>
<VL>111</VL>
<PG>791-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Downing-2000" MODIFIED="2008-10-13 10:00:26 +0100" MODIFIED_BY="[Empty name]" NAME="Downing 2000" TYPE="JOURNAL_ARTICLE">
<AU>Downing SW</AU>
<TI>Transmyocardial laser revascularization</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<PG>436-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fihn-2012" MODIFIED="2015-01-21 12:13:50 +0000" MODIFIED_BY="[Empty name]" NAME="Fihn 2012" TYPE="JOURNAL_ARTICLE">
<AU>Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al</AU>
<TI>2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2012</YR>
<VL>60</VL>
<NO>24</NO>
<PG>e44-e164</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Frazier-1995" MODIFIED="2008-10-13 10:00:45 +0100" MODIFIED_BY="[Empty name]" NAME="Frazier 1995" TYPE="JOURNAL_ARTICLE">
<AU>Frazier OH, Cooley DA, Kadipasaoglu KA, Pehlivanoglu S, Lindenmeir MH, Barasch E, et al</AU>
<TI>Myocardial revascularization with laser: preliminary findings</TI>
<SO>Circulation</SO>
<YR>1995</YR>
<VL>92</VL>
<NO>Suppl II</NO>
<PG>58-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-02-10 04:14:00 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne AC</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horvath-1996" MODIFIED="2008-10-13 10:01:04 +0100" MODIFIED_BY="[Empty name]" NAME="Horvath 1996" TYPE="JOURNAL_ARTICLE">
<AU>Horvath KA, Mannting F, Cummings N, Shernan SK, Cohn LH</AU>
<TI>Transmyocardial laser revascularization: operative techniques and clinical results at two years</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1996</YR>
<VL>111</VL>
<PG>1047-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jolicoeur-2012" MODIFIED="2015-02-10 04:15:31 +0000" MODIFIED_BY="[Empty name]" NAME="Jolicoeur 2012" TYPE="JOURNAL_ARTICLE">
<AU>Jolicoeur EM</AU>
<TI>Patients with coronary artery disease unsuitable for revascularization: definition, general principles, and a classification</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>2012</YR>
<VL>28</VL>
<PG>S50&#8211;S59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kim-2002" MODIFIED="2008-10-13 11:16:00 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kim MC, Kini A, Sharma SK</AU>
<TI>Refractory angina pectoris</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2002</YR>
<VL>39</VL>
<PG>923-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lange-1999" MODIFIED="2008-10-13 10:01:48 +0100" MODIFIED_BY="[Empty name]" NAME="Lange 1999" TYPE="JOURNAL_ARTICLE">
<AU>Lange RA, Hillis LD</AU>
<TI>Transmyocardial laser revascularization</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<PG>1075-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liao-2005" MODIFIED="2015-02-10 04:16:36 +0000" MODIFIED_BY="[Empty name]" NAME="Liao 2005" TYPE="JOURNAL_ARTICLE">
<AU>Liao L, Sarria-Santamera A, Matchar DB, Huntington AH, Lin S, Whellan DJ, et al</AU>
<TI>Meta-analysis of survival and relief of angina pectoris after transmyocardial revascularization</TI>
<SO>American Journal of Cardiology</SO>
<YR>2005</YR>
<VL>95</VL>
<PG>1243-5</PG>
<IDENTIFIERS MODIFIED="2008-10-13 10:24:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 10:24:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1016/j.amjcard.2005.01.057"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Macklin-1999" NAME="Macklin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Macklin R</AU>
<TI>The ethical problems with sham surgery in clinical research</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>13</NO>
<PG>992-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10498498"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Manchanda-2011" MODIFIED="2015-02-10 04:17:44 +0000" MODIFIED_BY="[Empty name]" NAME="Manchanda 2011" TYPE="JOURNAL_ARTICLE">
<AU>Manchanda A, Aggarwal A, Aggarwal N, Soran O</AU>
<TI>Management of refractory angina pectoris</TI>
<SO>Cardiology Journal</SO>
<YR>2011</YR>
<VL>18</VL>
<NO>4</NO>
<PG>343-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGuillion-2012" MODIFIED="2015-01-21 12:14:39 +0000" MODIFIED_BY="[Empty name]" NAME="McGuillion 2012" TYPE="JOURNAL_ARTICLE">
<AU>McGillion M, Arthur HM, Cook A, Carroll SL, Victor JC, L'allier PL, et al</AU>
<TI>Management of patients with refractory angina: Canadian Cardiovascular Society/Canadian Pain Society joint guidelines</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>2012</YR>
<VL>28</VL>
<NO>2 Suppl</NO>
<PG>S20-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mirhoseini-1982" MODIFIED="2008-10-13 10:25:25 +0100" MODIFIED_BY="[Empty name]" NAME="Mirhoseini 1982" TYPE="JOURNAL_ARTICLE">
<AU>Mirhoseini M, Muckerheide M, Cayton MM</AU>
<TI>Transventricular revascularization by laser</TI>
<SO>Lasers in Surgery and Medicine</SO>
<YR>1982</YR>
<VL>2</VL>
<PG>187-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mirhoseini-1993" MODIFIED="2015-02-10 04:18:13 +0000" MODIFIED_BY="[Empty name]" NAME="Mirhoseini 1993" TYPE="JOURNAL_ARTICLE">
<AU>Mirhoseini M, Shelgikar S, Cayton MM</AU>
<TI>Transmyocardial laser revascularization: a review</TI>
<SO>Journal of Clinical Laser Medicine and Surgery</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>15-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MSAC-1999" MODIFIED="2013-08-13 10:54:49 +0100" MODIFIED_BY="[Empty name]" NAME="MSAC 1999" TYPE="BOOK">
<AU>Medicare Service Advisory Committee</AU>
<SO>Transmyocardial laser revascularization</SO>
<YR>1999</YR>
<PB>Commonwealth of Australia</PB>
<CY>Canberra</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-N_x00e4_gele-1998" MODIFIED="2008-10-13 10:30:06 +0100" MODIFIED_BY="[Empty name]" NAME="Nägele 1998" TYPE="JOURNAL_ARTICLE">
<AU>Nägele H, Stubbe HM, Nienaber C, Rodiger W</AU>
<TI>Results of transmyocardial laser revascularization in non-revascularizable coronary artery disease after 3 years follow-up</TI>
<SO>European Heart Journal</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>10</NO>
<PG>1525-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peduzzi-1991" MODIFIED="2008-10-13 10:30:31 +0100" MODIFIED_BY="[Empty name]" NAME="Peduzzi 1991" TYPE="JOURNAL_ARTICLE">
<AU>Peduzzi P, Detre K, Wittes J, Holford T</AU>
<TI>Intent-to-treat analysis and the problem of crossovers. An example from the Veterans Administration coronary bypass surgery study</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1991</YR>
<VL>101</VL>
<PG>481-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peterson-2003" MODIFIED="2008-10-13 10:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Peterson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Peterson ED, Kaul P, Kaczmarek RG, Hammill BG, Armstrong PW, Bridges CR, et al</AU>
<TI>From controlled trials to clinical practice: monitoring transmyocardial revascularization use and outcomes</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>9</NO>
<PG>1611-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pr_x00ea_tre-1999" MODIFIED="2008-10-13 10:31:04 +0100" MODIFIED_BY="[Empty name]" NAME="Prêtre 1999" TYPE="JOURNAL_ARTICLE">
<AU>Prêtre R, Turina MI</AU>
<TI>Laser to the heart: magic but costly, or only costly?</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<PG>512-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Qaseen-2012" MODIFIED="2015-01-21 12:15:20 +0000" MODIFIED_BY="[Empty name]" NAME="Qaseen 2012" TYPE="JOURNAL_ARTICLE">
<AU>Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians</AU>
<TI>Management of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>157</VL>
<NO>10</NO>
<PG>735-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saririan-2003" MODIFIED="2014-06-16 11:26:51 +0100" MODIFIED_BY="[Empty name]" NAME="Saririan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Saririan M, Eisenberg MJ</AU>
<TI>Myocardial laser revascularization for the treatment of end-stage coronary artery disease</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>2</NO>
<PG>173-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schofield-2010" MODIFIED="2015-02-10 04:19:06 +0000" MODIFIED_BY="[Empty name]" NAME="Schofield 2010" TYPE="JOURNAL_ARTICLE">
<AU>Schofield PM, McNab D</AU>
<TI>NICE evaluation of transmyocardial laser revascularisation for refractory angina revascularisation and percutaneous laser</TI>
<SO>Heart</SO>
<YR>2010</YR>
<VL>96</VL>
<PG>312-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sharples-1999" MODIFIED="2008-10-13 10:31:21 +0100" MODIFIED_BY="[Empty name]" NAME="Sharples 1999" TYPE="JOURNAL_ARTICLE">
<AU>Sharples L, Schofield P, Caine N, Wallwork J</AU>
<TI>Transmyocardial laser revascularisation in clinical practice</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>1994-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-1995" MODIFIED="2008-10-13 10:31:49 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 1995" TYPE="JOURNAL_ARTICLE">
<AU>Smith JA, Dunning JJ, Parry AJ, Large SR, Wallwork J</AU>
<TI>Transmyocardial laser revascularization</TI>
<SO>Journal of Cardiac Surgery</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>5</NO>
<PG>569-72</PG>
<IDENTIFIERS MODIFIED="2008-10-13 10:31:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-13 10:31:49 +0100" MODIFIED_BY="[Empty name]" TYPE="CENTRAL" VALUE="CN-00120891"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smolina-2012" MODIFIED="2014-11-14 10:57:03 +0000" MODIFIED_BY="[Empty name]" NAME="Smolina 2012" TYPE="JOURNAL_ARTICLE">
<AU>Smolina K, Wright FL, Rayner M, Goldacre MJ</AU>
<TI>Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study</TI>
<SO>BMJ</SO>
<YR>2012</YR>
<VL>344</VL>
<PG>d8059</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wijeysundera-2010" MODIFIED="2015-01-21 12:15:46 +0000" MODIFIED_BY="[Empty name]" NAME="Wijeysundera 2010" TYPE="JOURNAL_ARTICLE">
<AU>Wijeysundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, et al</AU>
<TI>Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>303</VL>
<NO>18</NO>
<PG>1841-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-1999" MODIFIED="2015-02-10 04:19:46 +0000" MODIFIED_BY="[Empty name]" NAME="Williams 1999" TYPE="JOURNAL_ARTICLE">
<AU>Williams SG, Wright DJ, Lindsay SJ, Tan LB</AU>
<TI>Transmyocardial laser revascularisation in clinical practice</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>1994-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-2000" MODIFIED="2014-08-25 12:52:14 +0100" MODIFIED_BY="[Empty name]" NAME="Williams 2000" TYPE="JOURNAL_ARTICLE">
<AU>Williams SG, Wright DJ, Tan LB</AU>
<TI>Transmyocardial laser revascularization</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>342</VL>
<PG>436-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-06-16 11:31:05 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Briones-2009" MODIFIED="2014-06-16 11:31:05 +0100" MODIFIED_BY="[Empty name]" NAME="Briones 2009" TYPE="COCHRANE_REVIEW">
<AU>Briones E, Lacalle JR, Marin I</AU>
<TI>Transmyocardial laser revascularization versus medical therapy for refractory angina</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-06-16 11:28:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-06-16 11:28:38 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003712.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-02-25 09:19:45 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-02-25 09:19:45 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-02-25 09:09:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aaberge-2000">
<CHAR_METHODS MODIFIED="2015-02-11 00:58:06 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with parallel design. Single centre study</P>
<P>The National Hospital. Oslo. Norway. Duration: November 1995 - January 1998</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-25 09:09:09 +0000" MODIFIED_BY="[Empty name]">
<P>N: 100 randomized; 50 transmyocardial revascularization, 50 medical treatment</P>
<P>Mean age: 62.5, range 41-75. Male sex: 86%. Prior coronary artery bypass grafting: 85%. Prior percutaneous transluminal coronary angioplasty: 37%</P>
<P>Inclusion criteria: participants with an earlier angiogram and refusing CABG or PTCA, NYHA angina class III or IV</P>
<P>
<BR/>Exclusion criteria: mild symptoms (angina class under III), age &gt; 75 years, confirmed non-reversible ischaemia, ejection fraction &lt; 30%, general poor health status, inability to undergo study tests or refusal to participate in a RCT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-11 01:53:33 +0000" MODIFIED_BY="[Empty name]">
<P>Transmyocardial revascularization and optimal medical treatment combined versus optimal medical treatment alone</P>
<P>
<BR/>Dioxide carbon laser. Peak power laser 800 W. Pulses synchronized with R wave in ECG. One channel per square centimetre</P>
<P>No crossover allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-11 01:00:59 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: oxygen consumption and time to one millimetre of ST depression in exercise test</P>
<P>Secondary: morbidity and mortality during follow-up, improvement of angina class, other exercise test endpoints (time to chest pain, total exercise time and accumulated work)</P>
<P>Follow-up period: 12 months.</P>
<P>Quality of life was measured using SF36. A follow-up of 3-5 years was reported in a separate paper</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-11 01:01:23 +0000" MODIFIED_BY="[Empty name]">
<P>Trial Registration number: none available</P>
<P>Funding: supported by grants from the Norwegian Ministry of Health and Social Affairs</P>
<P>Declarations of interest: none presented</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-11 01:54:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allen-1999">
<CHAR_METHODS MODIFIED="2015-02-11 01:54:06 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with parallel design. Multicentre study</P>
<P>18 centres. USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-11 01:54:16 +0000" MODIFIED_BY="[Empty name]">
<P>N: 275 randomized; 132 transmyocardial revascularization, 143 medical treatment. 46 patients assigned to medical treatment only were withdrawn from the study and underwent transmyocardial laser revascularization under a parallel, FDA-approved protocol for patients who could not be weaned from intravenous antianginal medication</P>
<P>Mean age: 60. Male sex: 75%. Prior coronary artery bypass grafting: 86%. Prior percutaneous transluminal coronary angioplasty: 48%</P>
<P>Inclusion criteria: Refractory angina CCS class IV, not amenable to CABG or PTCA, reversible ischaemia determined by myocardial perfusion scanning, and ejection fraction &gt; 25%</P>
<P>Exclusion criteria: contraindication to general anaesthesia, severe chronic obstructive pulmonary disease, need of continued use of intravenous antianginal medication, inability to undergo dipyridamole-thallium stress scintigraphy, non Q-wave myocardial infarction in the previous two weeks, need of anticoagulant treatment, severe arrhythmias, and decompensated congestive heart failure</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-11 01:54:22 +0000" MODIFIED_BY="[Empty name]">
<P>Transmyocardial laser revascularization plus continued medical therapy and continued medical treatment alone</P>
<P>
<BR/>20 W Holmiun laser. Pulses were not gated to the cardiac cycle. One channel per squared centimetre. Mean number of channels per patient: 39<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-11 01:03:35 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: Reduction in two or more CCS angina classes. Treatment failure: death, Q-wave myocardial infarction, two cardiac-related hospitalizations in 3 months, or three in 12 months, inability to withdrawn intravenous antianginal medication on two attempts in a 48-hour period. Change in myocardial perfusion, measured by dipyridamole-thallium stress testing</P>
<P>Secondary: Free of cardiac-related rehospitalization, survival free of cardiac events, use of cardiac medications, performance on an exercise treadmill tests, and quality of life score</P>
<P>Follow-up period: 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 08:12:54 +0100" MODIFIED_BY="[Empty name]">
<P>Trial Registration number: none available.</P>
<P>Funding: supported by a grant from Eclipse Surgical Technologies, Sunnyvale, California.</P>
<P>Declarations of interest: none presented.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-11 01:54:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burkhoff-1999">
<CHAR_METHODS MODIFIED="2015-02-11 01:09:54 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with parallel design. Multicentre study. "Atlantic study"</P>
<P>16 centres. USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-11 01:10:11 +0000" MODIFIED_BY="[Empty name]">
<P>N: 182 randomized; 92 transmyocardial revascularization and continued medication, 90 continued medication alone</P>
<P>Mean age: 64, range 36-78. Male sex: 90%. Prior coronary artery bypass grafting: 90%. Prior percutaneous transluminal coronary angioplasty: 53%</P>
<P>Inclusion criteria: CCS angina class III-IV, ejection fraction &gt; 30%, reversible perfusion defects on dypiridamolle-thallium stress test, with at least one region of protected myocardium, angiographically defined</P>
<P>
<BR/>Exclusions: myocardial infarction in the previous 3 months, admitted to hospital for unstable angina in the last 21 days, severe symptomatic heart failure, ventricular arrhythmias, cardiac transplant or judged to be poor surgical candidate</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-11 01:54:56 +0000" MODIFIED_BY="[Empty name]">
<P>Transmyocardial laser revascularization with continued medication and continued medical treatment only<BR/>Holmium: YAG laser. One channel per square centimetre, with a median of 18 channels per patient</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-11 01:10:45 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: change in exercise duration on a standard protocol</P>
<P>Secondary: angina, quality of life, and dipyridamolle-thallium stress test</P>
<P>Follow-up period: 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-11 01:10:36 +0000" MODIFIED_BY="[Empty name]">
<P>Trial Registration number: none available</P>
<P>Funding: supported by CardioGenesis Corporation, Sunnyvale CA, USA</P>
<P>Declarations of interest: none presented</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-11 01:14:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frazier-1999">
<CHAR_METHODS MODIFIED="2015-02-11 01:13:41 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with parallel design. Multicenter study. "Transmyocardial Carbon Dioxide Laser Revascularization study"</P>
<P>12 centres. USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-11 01:14:06 +0000" MODIFIED_BY="[Empty name]">
<P>N: 192 randomized; 91 transmyocardial revascularization, 101 medical treatment. 60 patients assigned to medical treatment, who could not be weaned from intravenous antianginal medication, crossed-over to transmyocardial revascularization</P>
<P>Mean age: 61. Male sex: 79%. Prior coronary artery bypass grafting: 91%. Prior percutaneous transluminal coronary angioplasty: 50%</P>
<P>Inclusion criteria: CCS class III-IV angina, refractory to medical treatment, reversible ischaemia and coronary disease not amenable to CABG or PTCA</P>
<P>
<BR/>Excluded patients with ejection fraction under 20% or with a concurrent major disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-11 01:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Transmyocardial laser revascularization and continued medical treatment.<BR/>Carbon dioxide laser. Peak power 850W. One channel per square centimetre</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-11 01:14:37 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: Reduction of two or more angina classes</P>
<P>Others: mortality, morbidity, quality of life, SPECT scan</P>
<P>Follow-up period: 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-11 01:14:43 +0000" MODIFIED_BY="[Empty name]">
<P>Trial Registration number: none available</P>
<P>Funding: PLC Medical Systems, Franklin, Mass</P>
<P>Declarations of interest: none presented</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-11 01:55:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-1999">
<CHAR_METHODS MODIFIED="2015-02-11 01:16:23 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with parallel design. Single centre study</P>
<P>Missouri. USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-11 01:55:10 +0000" MODIFIED_BY="[Empty name]">
<P>N: 86 randomized; 43 transmyocardial revascularization, 43 medical treatment</P>
<P>Mean age: 62. Male sex: % not available. Prior coronary artery bypass grafting: 83%. Prior percutaneous transluminal coronary angioplasty: 50%</P>
<P>Inclusion criteria: CCS angina class 3-4, on maximal tolerated doses of at least two medications, and having areas of viable ischaemic myocardium by dypiridamole-thallium testing</P>
<P>Exclusion criteria: patients with left main coronary artery lesions greater than 70% without open bypasses to the anterior descending or circumflex arteries; patients with congestive heart failure; patients with obstructive pulmonary disease when, in opinion of the principal investigator, it would affect exercise testing</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-11 01:16:52 +0000" MODIFIED_BY="[Empty name]">
<P>Transmyocardial laser revascularization with continued medication and continued medical treatment only<BR/>Holmium: YAG laser. Operative protocol described as similar to the protocol by <LINK REF="REF-Horvath-1996" TYPE="REFERENCE">Horvath 1996</LINK>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-11 01:16:59 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: Improvement of angina score at 12 months. Endurance times on exercise treadmill</P>
<P>Follow-up period: 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-11 01:17:01 +0000" MODIFIED_BY="[Empty name]">
<P>Trial Registration number: none available</P>
<P>Funding: Cardiogenesis Corporation</P>
<P>Declarations of interest: none presented</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-11 01:55:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schofield-1999">
<CHAR_METHODS MODIFIED="2015-02-11 01:17:50 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with parallel design. Single centre study</P>
<P>Cambridge. United Kingdom. Recruitment period: October 1993 - September 1997</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-11 01:55:17 +0000" MODIFIED_BY="[Empty name]">
<P>N: 188 randomized; 94 transmyocardial revascularization, 94 medical treatment.</P>
<P>Mean age: 60. Male sex: 90%. Prior coronary artery bypass grafting: 93%. Prior percutaneous transluminal coronary angioplasty: 27%</P>
<P>Inclusion criteria: reversible ischaemia on radionuclide myocardial perfusion scan</P>
<P>Exclussion criteria: unable to do treadmill exercise testing, ejection fraction &lt; 30%, were suitable for conventional revascularization, were on intravenous therapy to control angina, or life expectancy &lt; 12 months because of non-cardiac disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-11 01:55:25 +0000" MODIFIED_BY="[Empty name]">
<P>Transmyocardial laser revascularization plus normal medical treatment and medical management only.<BR/>Carbon dioxide laser. Peak power: 850W. Laser pulse gated on the R wave. One channel per square centimetre. Median number of channels: 30 per patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-11 01:55:29 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: Duration of treadmill exercise test at 12 months. Reduction of two or more angina classes. Others: survival time, exercise test time, number of sites with reversible ischaemia.</P>
<P>Follow-up period: 12 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-11 01:19:14 +0000" MODIFIED_BY="[Empty name]">
<P>Trial Registration number: none available.</P>
<P>Funding: the Medical Research Council, service support for the research by the National Health Service Executive Research and Development Programme, treatment costs by National Health Service authorities, and a grant to obtain the laser equipment by BUPA Healthcare.</P>
<P>Declarations of interest: none presented</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-02-11 01:55:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-der-Sloot-2004">
<CHAR_METHODS MODIFIED="2015-02-11 01:20:04 +0000" MODIFIED_BY="[Empty name]">
<P>RCT with parallel design. Single centre study</P>
<P>Amsterdam, The Netherlands</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-02-11 01:55:33 +0000" MODIFIED_BY="[Empty name]">
<P>N: 30 randomized; 15 transmyocardial revascularization with continued maximal medication, 15 medical treatment only</P>
<P>Mean age: 61. Male sex: 94%. Prior coronary artery bypass grafting: 96%. Prior percutaneous transluminal coronary angioplasty: 22%</P>
<P>Inclusion criteria: angina NYHA class 3-4, refractory to conventional treatments and with detectable reversible myocardial ischaemia</P>
<P>
<BR/>Exclusion criteria: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-02-11 01:55:52 +0000" MODIFIED_BY="[Empty name]">
<P>Transmyocardial laser revascularization with continued maximal medication and medical treatment only.<BR/>XeCl excimer laser with wave length of 308 nm. One channel per square centimetre. Laser pulses were triggered 110-120 milliseconds after the R wave</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-02-11 01:20:37 +0000" MODIFIED_BY="[Empty name]">
<P>Primary: Angina score, myocardial perfusion and function, exercise tolerance, medication, major cardiac events and quality of life measures</P>
<P>Follow-up period: 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-02-11 01:20:41 +0000" MODIFIED_BY="[Empty name]">
<P>Trial Registration number: none available.</P>
<P>Funding: The Dutch Heart Foundation. Contract grant number: nr. 97-196. Quote: "This study was not sponsored by the industry; however, we express our genuine gratitude to Udo Roslan (1997&#8211;1998 working at Vascular Therapies, a division of the United States Surgical Co, Elancourt, France) who made it possible to begin this trial by guaranteeing financial support, if necessary."</P>
<P>Declarations of interest: none presented</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CABG = coronary artery bypass graft; CCS = Canadian Cardiovasclar Society; ECG = Electrocardiogram; FDA = Food and Drug Administration; IQR = interquartile range; NYHA = New York Heart Association; PTCA = percutaneous transluminal coronary angioplasty; QOL = quality of life; RCT = randomized controlled trial; TMLR = transmyocardial laser revascularization</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-02-11 01:56:04 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Allen-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of TMLR combined with CABG versus CABG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-16 11:25:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Appelman-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-16 11:25:30 +0100" MODIFIED_BY="[Empty name]">
<P>No refractory angina patients. Comparison of laser angioplasty versus balloon angioplasty</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-16 11:25:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Appelman-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-16 11:25:25 +0100" MODIFIED_BY="[Empty name]">
<P>No refractory angina patients. Comparison of laser angioplasty versus balloon angioplasty</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-16 11:25:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Appelman-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-16 11:25:27 +0100" MODIFIED_BY="[Empty name]">
<P>No refractory angina patients. Comparison of laser angioplasty versus balloon angioplasty</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dixon-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of PTMR versus angioplasty combined with PTMR</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dowling-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>The objective was to prevent post-surgical pain, and surgical procedures were PTMR combined with CABG versus CABG only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dziuk-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of TMLR alone versus TMLR combined with CABG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-11 01:24:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frazier-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-11 01:24:40 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of TMLR combined with CABG versus CABG</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Guleserian-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of TMLR versus TMLR combined with CABG. No random allocation of patients to treatment groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Horvath_x002c_-2000a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Narrative overview of studies on TMLR</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Horvath_x002c_-2000b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Narrative overview of studies on TMLR</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Horvath_x002c_-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Narrative overview of studies on TMLR</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-13 10:44:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horvath_x002c_-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-13 10:44:24 +0100" MODIFIED_BY="[Empty name]">
<P>Narrative overview of studies on TMLR</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kniazeva-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Laser procedure without thoracotomy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leon-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Results of PTMR instead of TMLR, and the control group was not receiving medical treatment, but sham procedure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Loubani-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of CABG versus CABG combined with TMLR</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McNab-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of spinal cord stimulation versus percutaneous laser myocardial revascularization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-11 01:25:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Milano-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-11 01:25:05 +0000" MODIFIED_BY="[Empty name]">
<P>Non-comparative study, reporting data only on TMLR treated patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-13 13:29:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Myers-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-13 13:29:08 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison of TMLR versus percutaneous laser myocardial revascularization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oesterle-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pilot study on percutaneous laser myocardial revascularization without medical treatment group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oesterle-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of percutaneous laser myocardial revascularization versus medical treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salem-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of percutaneous laser myocardial revascularization versus sham surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salem-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of percutaneous laser myocardial revascularization versus sham surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salem-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of percutaneous laser myocardial revascularization versus sham surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stone-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparison of percutaneous laser myocardial revascularization versus medical treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-02-11 01:56:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vasil_x0027_ev-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-02-11 01:56:04 +0000" MODIFIED_BY="[Empty name]">
<P>Non refractory angina patients. No randomisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-06-16 11:22:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-06-16 11:22:09 +0100" MODIFIED_BY="[Empty name]">
<P>Comparison of percutaneous laser myocardial revascularization plus medical treatment versus medical treatment alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CABG = coronary artery bypass graft; PTCA = percutaneous transluminal coronary angioplasty; PTMR = Percutaneous myocardial revascularization; TMLR = transmyocardial laser revascularization</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-06-19 11:24:39 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-02-11 01:56:04 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-02-11 01:56:04 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:53:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aaberge-2000">
<DESCRIPTION>
<P>Mentioned as randomized but sequence generation procedure not described. Quote: "patients were randomized 1:1 using block-randomization into two comparable groups to achieve either continued optimal medical treatment alone (MT group), or optimal medical treatment in combination with transmyocardial revascularization with CO2-laser (TMR group)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:54:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allen-1999">
<DESCRIPTION>
<P>Mentioned as randomized but sequence generation procedure not described. Quote: "Randomization was performed by each center on a 1:1 basis, with a block size of six patients per center"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:55:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burkhoff-1999">
<DESCRIPTION>
<P>Central randomisation. Sequence generation procedure not described. Quote: "We used block randomisation according to site to achieve roughly equal distribution between groups at each site. Randomization was done by a central coordinating centre by telephone. The co-ordinating centre confirmed eligibility criteria before it provided a randomisation assignment. Six patients had minor deviations from protocol related to entry criteria but were included in analyses"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:55:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frazier-1999">
<DESCRIPTION>
<P>Central randomisation but sequence generation procedure not described.</P>
<P>Quote: "By means of randomisation at a central institution, patients were assigned, in a 1:1 ratio"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:17:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1999">
<DESCRIPTION>
<P>Sequence generation procedure not described. Quote:"candidates at our primary single institution were randomized to 2 study groups by an independent data management group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:19:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schofield-1999">
<DESCRIPTION>
<P>Quote: "A simple randomisation list was generated and held by the trial's statistician"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:56:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Sloot-2004">
<DESCRIPTION>
<P>Sequence generation procedure not described. Quote: "This study was designed as a randomized single-center trial consisting of 30 patients. When 2 subsequent patients met the criteria they were included as a pair, randomized between excimer TMLR and continued maximal medication, and then followed simultaneously for 1 year. At randomisation patients assigned to continued maximal medication were offered to undergo TMLR after 1 year follow-up (no earlier)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-02-11 01:55:05 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:53:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aaberge-2000">
<DESCRIPTION>
<P>Quote: "After inclusion, each patient received an allocation number. Randomization was then performed by opening consecutively numbered sealed envelopes with allocation numbers and treatment inside. One patient initially withdrew from the operation, but later changed his mind and was operated on three months after randomisation; he has been followed up as patient who has received the operation. All other patients were operated on within two weeks after randomisation. Evaluation, randomisation and follow-up were done at The National Hospital"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:03:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Allen-1999">
<DESCRIPTION>
<P>Not reported. Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:55:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burkhoff-1999">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:55:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frazier-1999">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:17:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jones-1999">
<DESCRIPTION>
<P>Not reported. Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:19:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schofield-1999">
<DESCRIPTION>
<P>Quote: "For practical reasons, randomisation was by consecutively numbered opaque sealed envelopes which were opened by a research fellow after the patient had given informed consent; this investigator was masked to the contents before opening. Allocation was returned to the trial coordinator and the number of patients assigned to each group was checked against the statisticians&#8217; list"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:21:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-der-Sloot-2004">
<DESCRIPTION>
<P>Not reported. Probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-08-08 08:54:30 +0100" MODIFIED_BY="Liz Bickerdike" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-02-11 01:21:02 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.02" NO="2">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1" REF_IDS="CMP-001.01 CMP-001.02 CMP-001.07 CMP-001.08 CMP-001.09 CMP-001.10">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-11 01:01:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aaberge-2000">
<DESCRIPTION>
<P>Open study. Evaluation of subjective outcomes is likely to be affected by the lack of blindness. Quote: "The investigation was designed as an open, prospective, single center study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-02-11 01:02:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aaberge-2000">
<DESCRIPTION>
<P>Open study. Evaluation of objective outcomes is not likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-11 01:03:52 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Allen-1999">
<DESCRIPTION>
<P>Not reported. Probably unblinded. Evaluation of subjective outcomes is likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-02-11 01:03:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-1999">
<DESCRIPTION>
<P>Not reported. Probably unblinded, but evaluation of objective outcomes is not likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-11 01:11:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Burkhoff-1999">
<DESCRIPTION>
<P>Unblinded. Evaluation of subjective outcomes is likely to be affected by the lack of blindness</P>
<P>Quote: "Angina improvement may be due to a placebo effect, a factor that cannot be excluded in unmasked studies of angina relief"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-02-11 01:11:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burkhoff-1999">
<DESCRIPTION>
<P>Unblinded, but evaluation of objective outcomes is not likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-11 01:15:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Frazier-1999">
<DESCRIPTION>
<P>Unblinded. Evaluation of subjective outcomes is likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-02-11 01:15:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frazier-1999">
<DESCRIPTION>
<P>Unblinded, but evaluation of objective outcomes is not likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-11 01:17:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jones-1999">
<DESCRIPTION>
<P>Unblinded. Evaluation of subjective outcomes is likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-02-11 01:17:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jones-1999">
<DESCRIPTION>
<P>Unblinded, but evaluation of objective outcomes is not likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-11 01:19:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schofield-1999">
<DESCRIPTION>
<P>Unblinded. Evaluation of subjective outcomes is likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-02-11 01:19:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schofield-1999">
<DESCRIPTION>
<P>Unblinded, but evaluation of objective outcomes is not likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-02-11 01:21:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-der-Sloot-2004">
<DESCRIPTION>
<P>Unblinded. Evaluation of subjective outcomes is likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.02" MODIFIED="2015-02-11 01:21:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Sloot-2004">
<DESCRIPTION>
<P>Unblinded, but evaluation of objective outcomes is not likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-02-11 01:21:03 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.02" NO="2">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1" REF_IDS="CMP-001.01 CMP-001.02 CMP-001.07 CMP-001.08 CMP-001.09 CMP-001.10">
<NAME>Subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-11 01:02:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Aaberge-2000">
<DESCRIPTION>
<P>Open study. Evaluation of subjective outcomes is likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-02-11 01:02:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aaberge-2000">
<DESCRIPTION>
<P>Open study. Evaluation of objective outcomes is not likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-11 01:03:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-1999">
<DESCRIPTION>
<P>Blinded. Quote: "An independent laboratory (at the Cleveland Clinic Foundation, Cleveland) conducted a masked assessment of angina and quality of life at 12 months"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-02-11 01:08:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-1999">
<DESCRIPTION>
<P>Blinded. Quote: "Computerized quantification of ischemic changes, perfusion defects at rest, and delayed perfusion defects was performed in a masked manner by an independent laboratory."</P>
<P>Quote: "A blinded, independent data and safety monitoring committee monitored the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-11 01:11:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burkhoff-1999">
<DESCRIPTION>
<P>Blinded. Quote: "All endpoint data were assessed by central laboratory investigators who were unaware of treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-02-11 01:11:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burkhoff-1999">
<DESCRIPTION>
<P>Blinded. Quote: "All endpoint data were assessed by central laboratory investigators who were unaware of treatment group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-11 01:15:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Frazier-1999">
<DESCRIPTION>
<P>Quote: "A blinded, independent assessment of angina was conducted in addition to the on-site evaluations."</P>
<P>However the results of that independent evaluation were not presented in the publication. Authors only mentioned that: "For 80 percent of the patients, the result of the independent assessment was within one CCS class of the result of the on-site assessment, indicating consistency in the evaluations. When the on-site and independent evaluations were compared, no significant differences were found (P = 0.20)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-02-11 01:15:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Frazier-1999">
<DESCRIPTION>
<P>Unblinded, but evaluation of objective outcomes is not likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-12 10:15:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Jones-1999">
<DESCRIPTION>
<P>Nothing mentioned about angina assessment, probably unblinded. Evaluation of subjective outcomes is likely to be affected by the lack of blindness. </P>
<P>Blinded for exercise tests. Quote: "Those monitoring the exercise tests were blinded to the group assignment of patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-02-11 01:17:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jones-1999">
<DESCRIPTION>
<P>Blinded. Quote: " Results, including ETTs, echocardiograms, and thallium scans, were sent to a core laboratory, blind to the individual group assignments, for final interpretation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-12 10:25:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schofield-1999">
<DESCRIPTION>
<P>Nothing mentioned about angina and exercise test assessments, probably unblinded. Evaluation of subjective outcomes is likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-02-11 01:19:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schofield-1999">
<DESCRIPTION>
<P>Evaluation of objective outcomes is not likely to be affected by the lack of blindness.</P>
<P>Quote: "All scans processed by 1 investigator blinded to patient identity and treatment assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-02-11 01:21:03 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-der-Sloot-2004">
<DESCRIPTION>
<P>Nothing mentioned about it, probably unblinded. Evaluation of subjective outcomes is likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.02" MODIFIED="2015-02-11 01:21:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Sloot-2004">
<DESCRIPTION>
<P>Nothing mentioned about it, probably unblinded, but evaluation of objective outcomes is not likely to be affected by the lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-02-11 01:21:08 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-11 01:02:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aaberge-2000">
<DESCRIPTION>
<P>No losses in the follow-up reported. Quote: "Follow-up of patients after three and 12 months was complete. However, one patient in each group did not perform the exercise tests after 12 months: one because of a cerebral hemorrhage and inability to perform tests and one for personal reasons"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-11 01:08:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Allen-1999">
<DESCRIPTION>
<P>Primary end-point "angina": missing outcome data for more than one-third of the patients and no information provided about the reasons for it. 132 patients were initially allocated to TMLR and 143 to medical therapy alone but only 97 of them received that medical therapy alone given that 46 crossed to TMLR, which left overall 229 patients to follow-up. 33 patients died before one year, 21 in the TMLR group and 12 in the medical treatment group; that would leave 196 patients. For 12 months follow-up authors provided information for only 126 patients; not presenting data on 70 patients.</P>
<P>Quote: "Angina was evaluated at 3, 6, and 12 months in all surviving patients who were not crossed over to surgical treatment and who had reached the designated follow-up time (hereafter referred to as eligible patients): 213 of 221 patients (96%) at 3 months, 172 of 183 (94% per cent) at 6 months, and 126 of 136 (93%) at 12 months."</P>
<P>Quote: "The Duke Activity Status Index was used to assess the quality of life. The index is based on a scale from 0 to 58, with higher scores indicating greater functional capacity. Among the first 160 patients<BR/>enrolled in the study, these assessments were performed at 12 months in 112 of 132 eligible patients (85%)."</P>
<P>Quote: "Data on treatment failure were available at 12 months for 273 of 275 patients (99%)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-11 01:12:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burkhoff-1999">
<DESCRIPTION>
<P>Withdrawals and reasons clearly presented, balanced among comparison groups and unlikely to bias the results. </P>
<P>Quote: "16 patients withdrew from the study, nine in the TMLR group and seven in the medication-only group, all voluntarily. Although complete follow-up test results were not available for these patients, each one was contacted and was alive at 12 months. After deaths and withdrawals had been accounted for, 152 patients (78 in the TMLR group, 74 in the medication-only group) reached the end of the study and were assessed for angina. Of these, 74 (95%) in the TMLR group and 67 (91%) in the medication only group completed the exercise-tolerance test at 12 months"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-11 01:15:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frazier-1999">
<DESCRIPTION>
<P>6 patients lost to follow-up, 2 in each group (laser, medical treatment and cross-over groups)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-11 01:17:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jones-1999">
<DESCRIPTION>
<P>Quote: "All but 2 living patients were followed for 12 months"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-11 01:19:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schofield-1999">
<DESCRIPTION>
<P>Number of withdrawals and reasons detailed in the report. Analyzed at one year for primary endpoint: 83 out of 94 assigned to medical treatment only and 77 out of 94 for the laser group. Quote: "One TMLR patient, with a history of alcohol abuse, was lost to follow-up. Five medical-management patients withdrew soon after recruitment because they were unhappy about their treatment allocation. The remaining four non-attenders (three TMLR, one medical management) were unwell or had personal problems or commitments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-02-11 01:21:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Sloot-2004">
<DESCRIPTION>
<P>Quotes: "No patients were lost to follow-up. No data were missing at base line and at 12 months." "In both groups, missing QOL scores were substituted using linear interpolation, except when the 1 month FU was missing in the TMLR group. Then, the average (TMLR) group changes were used to calculate substitutes for the missing values. In case of missing data due to mortality, the last observations obtained before death were used as input for the remaining FU moments (&#8216;last observation carried forward&#8217;)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-02-11 01:21:15 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:02:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aaberge-2000">
<DESCRIPTION>
<P>Study protocol not available but published report included main outcomes of interest. Quote: "Predefined primary end points were time to one millimeter of ST segment depression and MVO<SUB>2</SUB>. Secondary end points were time to chest pain, total exercise time and accumulated work"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:07:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Allen-1999">
<DESCRIPTION>
<P>Study protocol not available but published report included main outcomes of interest</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:12:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burkhoff-1999">
<DESCRIPTION>
<P>Study protocol not available but published report included main outcomes of interest</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:15:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Frazier-1999">
<DESCRIPTION>
<P>Study protocol not available but published report included main outcomes of interest</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:17:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jones-1999">
<DESCRIPTION>
<P>Study protocol not available but published report included main outcomes of interest</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:19:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schofield-1999">
<DESCRIPTION>
<P>Study protocol not available but published report included main outcomes of interest</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:21:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-der-Sloot-2004">
<DESCRIPTION>
<P>Study protocol not available but published reports included main outcomes of interest</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2015-02-11 01:56:04 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:02:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aaberge-2000">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias. No significant differences in baseline characteristics of patients between the treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:54:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Allen-1999">
<DESCRIPTION>
<P>Quote: "The demographic and clinical characteristics of the patients in the two treatment groups were similar." But baseline characteristics of compared groups were unbalanced in relation with a clinically relevant feature. Among the patients initially randomized to "medical treatment" 32% could not be weaned from intravenous antianginal medication and underwent transmyocardial revascularization. If randomisation performed well, among the patients initially randomized to the laser group we would expected a similar percentage of around 32% that made them directly eligible for TMLR. </P>
<P>Quote: "The improvement in angina in the medical-therapy group at 12 months reflects the reduction in the number of patients in this group as the sicker patients were withdrawn so that they could undergo transmyocardial revascularization under a separate protocol."</P>
<P>"Quote: "Forty-six patients (32 percent) initially assigned to receive medical therapy alone met the a priori criteria for treatment failure and could not be weaned from intravenous antianginal medication on two attempts over a period of 48 hours. They were withdrawn from the study and underwent transmyocardial revascularization under a parallel, FDA-approved protocol for patients who could not be weaned from intravenous antianginal medications. Thus, there were three groups of patients: those randomly assigned to undergo transmyocardial revascularization and to receive continued medical therapy (132 patients), those who received medical therapy alone throughout the study (97), and those randomly assigned to receive medical therapy alone who met the criteria for treatment failure and underwent transmyocardial revascularization as part of a separate protocol (46). The third group of patients is hereafter referred to as the crossover group."</P>
<P>Composite outcome measure "Treatment failure" includes many components and counts them as equivalent when they have different relevance for the patients: e.g. having "two cardiac-related hospitalizations in 3 months" counts the same as "death"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:13:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burkhoff-1999">
<DESCRIPTION>
<P>Some imbalance among baseline variables between compared groups. Quote: "Age, sex, and baseline variables were similar in the two groups, although there were higher frequencies of hypertension and hypercholesterolaemia and higher disease perception score on the Seattle angina questionnaire in the medication-only group."</P>
<P>In the methods sections authors stated: "Statistical analysis. The primary outcome measure was the change in exercise duration on a standard protocol. We designed the study to detect a difference of 60 s, which we took to be clinically important, in the mean change from baseline in the TMLR group compared with the medication-only group, with a power of 80% and a level of significance of 0·05." But in the publication they do not present mean changes but medians and ranges or IQR. Quote: "Results are presented as medians and ranges or IQR."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:55:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Frazier-1999">
<DESCRIPTION>
<P>60 out of 101 of patients randomized to medical treatment crossed over to laser treatment.</P>
<P>Quote: "Crossover from medical treatment to transmyocardial revascularization was allowed if a patient had unstable angina that necessitated intravenous antianginal therapy for 48 hours or more in an intensive care unit. After crossover, patients were followed for an additional 12 months, regardless of how long they had been in the group assigned to medical treatment. These patients were considered part of the medical-treatment group until crossover, after which they were followed separately."</P>
<P>If randomisation performed well, among the patients initially randomized to the laser group we would expected a similar percentage of around 60% with unstable angina that made eligible directly for laser therapy. So clinical baseline characteristics of compared groups were unbalanced in relation with a clinical relevant feature, stability of the angina, circumstance that could bias the evaluation of the impact of compared treatments.</P>
<P>Quote: "The option for crossover from the medical-treatment group to the transmyocardial-revascularization group was the greatest limitation of this study. Crossover was allowed as an incentive for patients assigned to maximal medical therapy to remain in the study if medical therapy failed"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:17:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jones-1999">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias. No significant differences in baseline characteristics of patients between the treatment groups, except for hypertension. Higher prevalence of hypertension on those randomized to medical treatment (83.7% vs 62.8%; P = 0.03), although authors examined it by multivariate analysis and had no effect on endpoints</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:19:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schofield-1999">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias. No significant differences in baseline characteristics of patients between the treatment groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-02-11 01:56:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-van-der-Sloot-2004">
<DESCRIPTION>
<P>Quote: "As mentioned above, there are two important points in this study which may be considered limitations, as they could have created bias in the QOL results. The first limitation is the assessment of baseline QOL scores after randomisation. This may have created a positive baseline bias in the treatment group as well as a negative bias in the control group. The latter could also play a role as a consequence of the study design (i.e., non-blinded).</P>
<P>Cross-over offered to the patients allocated to medical treatment. Quote: "The second limitation which could have introduced a bias is the fact that at baseline, patients randomized to the control group were offered treatment after they had completed their 1 year FU. This may have introduced a positive anticipation bias, especially towards the end of theFU period when they were about to be treated"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-02-11 01:49:40 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-02-11 01:49:40 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-02-11 00:51:35 +0000" MODIFIED_BY="[Empty name]">Transmyocardial laser revascularization compared to medical treatment for refractory angina</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Transmyocardial laser revascularization compared to medical treatment for refractory angina</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with refractory angina<BR/>
<B>Settings: </B>hospital care<BR/>
<B>Intervention:</B> Transmyocardial laser revascularization<BR/>
<B>Comparison: </B>Medical treatment</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No. of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Medical treatment</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Transmyocardial laser revascularization</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Angina reduction</B>
</P>
<P>Decrease in two angina classes or more</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 4.63 </B>
<BR/>(3.43 to 6.25)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1051<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>148 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>445 per 1000</B>
<BR/>(373 to 520)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>32 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>133 per 1000</B>
<BR/>(102 to 171)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Angina reduction - CCS score</B>
</P>
<P>Decrease in two angina classes or more</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 3.95 </B>
<BR/>(2.9 to 5.39)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>923<BR/>(5 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>168 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>443 per 1000</B>
<BR/>(369 to 521)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>89 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>278 per 1000</B>
<BR/>(221 to 345)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Angina reduction - NYHA scale</B>
</P>
<P>Decrease in two angina classes or more</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 68.32 </B>
<BR/>(7.95 to 587.38)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>128<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Overall mortality</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 1.12 </B>
<BR/>(0.77 to 1.63)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1053<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>112 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>124 per 1000</B>
<BR/>(88 to 170)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>111 per 1000</B>
<BR/>(79 to 153)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Early postoperative mortality</B>
</P>
<P>Deaths in the 30 days after surgery</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 1.19 </B>
<BR/>(0.63 to 2.24)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>967<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>34 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>41 per 1000</B>
<BR/>(22 to 74)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Exercise tolerance</B>
</P>
<P>Minutes</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean exercise tolerance in the intervention groups was<BR/>
<B>25.22 higher</B>
<BR/>(35.28 lower to 85.72 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>129<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CCS</B>: Canadian Cardiovascular Society; <B>CI:</B> Confidence interval; <B>NYHA</B>: New York Heart Association; <B>OR:</B> Odds ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Unblinded studies. Evaluation of subjective outcomes is likely to be affected by the lack of blindness. Randomization procedures unclear in all the studies, except one.<BR/>
<SUP>2</SUP> Angina reduction: High statistical heterogeneity: I<SUP>2</SUP> = 83%. P &lt; 0.00001.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-02-11 01:56:09 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-02-11 01:56:09 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Primary and secondary outcomes, reported by authors</TITLE>
<TABLE COLS="3" ROWS="8">
<TR>
<TH VALIGN="BOTTOM">
<P>Study</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Primary outcomes</P>
</TH>
<TH VALIGN="BOTTOM">
<P>Secondary outcomes</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Aaberge-2000" TYPE="STUDY">Aaberge 2000</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Time to one millimetre ST depression and MVO2</P>
</TD>
<TD VALIGN="TOP">
<P>Time to chest pain, total exercise time and accumulated work</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Allen-1999" TYPE="STUDY">Allen 1999</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Change in angina symptoms, treatment failure and change in myocardial perfusion</P>
</TD>
<TD VALIGN="TOP">
<P>Freedom from cardiac-related hospitalization, survival free of cardiac events, use of cardiac medications, performance on treadmill test, and quality of life score</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Burkhoff-1999" TYPE="STUDY">Burkhoff 1999</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Change in exercise duration on a standard protocol</P>
</TD>
<TD VALIGN="TOP">
<P>Angina, quality of life, and dipyridamole thallium stress test</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Frazier-1999" TYPE="STUDY">Frazier 1999</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported explicitly by the authors</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported explicitly by the authors</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jones-1999" TYPE="STUDY">Jones 1999</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported explicitly by the authors</P>
</TD>
<TD VALIGN="TOP">
<P>Not reported explicitly by the authors</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schofield-1999" TYPE="STUDY">Schofield 1999</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Duration of treadmill exercise test at 12-months follow-up</P>
</TD>
<TD VALIGN="TOP">
<P>Left ventricular ejection fraction by radionuclide multigated acquisition scan; chest pain perceived by patients. CCS score was not part of the original trial protocol but included later</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-van-der-Sloot-2004" TYPE="STUDY">van der Sloot 2004</LINK>
</P>
</TD>
<TD VALIGN="TOP">
<P>Improvement of angina at 12-months follow-up</P>
</TD>
<TD VALIGN="TOP">
<P>Medical treatment, clinical events, quality of life, exercise time, and myocardial perfusion and function</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-02-11 01:27:27 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-02-11 01:27:27 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Transmyocardial laser revascularization versus medical treatment</NAME>
<DICH_OUTCOME CHI2="34.41146022627006" CI_END="6.246225152860315" CI_START="3.426289828720429" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="4.62616230899252" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="79" I2="82.56394828772905" I2_Q="84.85977569257199" ID="CMP-001.01" LOG_CI_END="0.7956176348545465" LOG_CI_START="0.5348240970095662" LOG_EFFECT_SIZE="0.6652208659320564" METHOD="MH" MODIFIED="2008-10-03 15:22:44 +0100" MODIFIED_BY="Liz Bickerdike" NO="1" P_CHI2="5.602005095250995E-6" P_Q="0.010169761899500918" P_Z="1.5428205338814934E-23" Q="6.604921959507462" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="516" TOTAL_2="535" WEIGHT="99.99999999999999" Z="9.998782560067747">
<NAME>Angina reduction</NAME>
<GROUP_LABEL_1>Favours treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="24.789675657070866" CI_END="5.389016406813931" CI_START="2.896342951833057" DF="4" EFFECT_SIZE="3.950751787595398" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="79" I2="83.86425036239204" ID="CMP-001.01.01" LOG_CI_END="0.7315095058038393" LOG_CI_START="0.4618499847593279" LOG_EFFECT_SIZE="0.5966797452815836" NO="1" P_CHI2="5.545373849880075E-5" P_Z="4.1835823664040136E-18" STUDIES="5" TAU2="0.0" TOTAL_1="452" TOTAL_2="471" WEIGHT="98.95074406078518" Z="8.673684552479779">
<NAME>CCS score</NAME>
<DICH_DATA CI_END="2.7936162620685736" CI_START="1.0429246236879859" EFFECT_SIZE="1.706906906906907" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="45" LOG_CI_END="0.4461667501275983" LOG_CI_START="0.01825292137062631" LOG_EFFECT_SIZE="0.23220983574911228" ORDER="8910" O_E="0.0" SE="0.2513587012194597" STUDY_ID="STD-Allen-1999" TOTAL_1="132" TOTAL_2="143" VAR="0.06318119667873362" WEIGHT="57.02344148041811"/>
<DICH_DATA CI_END="24.628552982607964" CI_START="4.653497906840902" EFFECT_SIZE="10.705555555555556" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="8" LOG_CI_END="1.3914388962024997" LOG_CI_START="0.6677795229017941" LOG_EFFECT_SIZE="1.029609209552147" ORDER="8911" O_E="0.0" SE="0.42508109804850486" STUDY_ID="STD-Burkhoff-1999" TOTAL_1="92" TOTAL_2="90" VAR="0.1806939399181226" WEIGHT="9.31478848061478"/>
<DICH_DATA CI_END="5.906118498940721" CI_START="1.7066364389177937" EFFECT_SIZE="3.174838112858464" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="23" LOG_CI_END="0.7713021562964806" LOG_CI_START="0.23214101415023447" LOG_EFFECT_SIZE="0.5017215852233574" ORDER="8912" O_E="0.0" SE="0.31670592378740187" STUDY_ID="STD-Frazier-1999" TOTAL_1="91" TOTAL_2="101" VAR="0.10030264216203161" WEIGHT="26.51345652854619"/>
<DICH_DATA CI_END="3083.5493238432905" CI_START="10.16004503568374" EFFECT_SIZE="177.0" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="0" LOG_CI_END="3.489050899706265" LOG_CI_START="1.0068956330173482" LOG_EFFECT_SIZE="2.247973266361807" ORDER="8913" O_E="0.0" SE="1.4580302905197997" STUDY_ID="STD-Jones-1999" TOTAL_1="43" TOTAL_2="43" VAR="2.1258523280732518" WEIGHT="0.387969172985202"/>
<DICH_DATA CI_END="25.317922976299453" CI_START="2.038590643266523" EFFECT_SIZE="7.184210526315789" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="3" LOG_CI_END="1.4034280742943084" LOG_CI_START="0.30933002655358327" LOG_EFFECT_SIZE="0.8563790504239459" ORDER="8914" O_E="0.0" SE="0.6426786091155843" STUDY_ID="STD-Schofield-1999" TOTAL_1="94" TOTAL_2="94" VAR="0.413035794614742" WEIGHT="5.711088398220905"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.012007174909404549" CI_END="587.3801665708345" CI_START="7.946784119456955" DF="1" EFFECT_SIZE="68.3211781206171" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="0" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="2.7689192780835055" LOG_CI_START="0.9001914152313069" LOG_EFFECT_SIZE="1.8345553466574063" NO="2" P_CHI2="0.9127446509817676" P_Z="1.1896648335879524E-4" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="64" WEIGHT="1.0492559392148069" Z="3.848246155655783">
<NAME>NYHA scale</NAME>
<DICH_DATA CI_END="1086.7556384612988" CI_START="3.686447311107184" EFFECT_SIZE="63.295081967213115" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" LOG_CI_END="3.0361319021375706" LOG_CI_START="0.5666080310889933" LOG_EFFECT_SIZE="1.801369966613282" ORDER="8915" O_E="0.0" SE="1.4506105461942476" STUDY_ID="STD-Aaberge-2000" TOTAL_1="49" TOTAL_2="49" VAR="2.104270956729973" WEIGHT="0.7181443174429533"/>
<DICH_DATA CI_END="1622.841917765985" CI_START="3.8673886994901934" EFFECT_SIZE="79.22222222222223" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="3.210276216939207" LOG_CI_START="0.5874178238858746" LOG_EFFECT_SIZE="1.8988470204125407" ORDER="8916" O_E="0.0" SE="1.540680003437966" STUDY_ID="STD-van-der-Sloot-2004" TOTAL_1="15" TOTAL_2="15" VAR="2.3736948729936107" WEIGHT="0.3311116217718535"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.450603051495081" CI_END="18.51233229403816" CI_START="7.410451580511934" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="11.712589043730564" ESTIMABLE="YES" EVENTS_1="246" EVENTS_2="30" I2="8.26703113835234" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.2674611372090103" LOG_CI_START="0.869844673964317" LOG_EFFECT_SIZE="1.0686529055866636" METHOD="MH" MODIFIED="2015-02-11 01:26:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36339292844793625" P_Q="1.0" P_Z="5.934013565284749E-26" Q="0.0" RANDOM="NO" SCALE="807.83" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="416" TOTAL_2="282" WEIGHT="100.00000000000001" Z="10.535384726436618">
<NAME>Angina reduction (as-treated)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1086.7556384612988" CI_START="3.686447311107184" EFFECT_SIZE="63.295081967213115" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" LOG_CI_END="3.0361319021375706" LOG_CI_START="0.5666080310889933" LOG_EFFECT_SIZE="1.801369966613282" ORDER="8952" O_E="0.0" SE="1.4506105461942476" STUDY_ID="STD-Aaberge-2000" TOTAL_1="49" TOTAL_2="49" VAR="2.104270956729973" WEIGHT="2.4625095443438814"/>
<DICH_DATA CI_END="14.876903196869483" CI_START="3.3985772112594907" EFFECT_SIZE="7.110576923076923" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="16" LOG_CI_END="1.1725125370914207" LOG_CI_START="0.5312971409768411" LOG_EFFECT_SIZE="0.851904839034131" ORDER="8953" O_E="0.0" SE="0.3766530977451055" STUDY_ID="STD-Allen-1999" TOTAL_1="113" TOTAL_2="50" VAR="0.14186755604098403" WEIGHT="41.211061870544285"/>
<DICH_DATA CI_END="30.246500808474327" CI_START="5.357038986221523" EFFECT_SIZE="12.729166666666666" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="8" LOG_CI_END="1.4806751387414616" LOG_CI_START="0.7289248069924725" LOG_EFFECT_SIZE="1.104799972866967" ORDER="8954" O_E="0.0" SE="0.44158186609351335" STUDY_ID="STD-Burkhoff-1999" TOTAL_1="77" TOTAL_2="73" VAR="0.19499454446262957" WEIGHT="25.836165711148922"/>
<DICH_DATA CI_END="49.642149066760965" CI_START="3.6344372803378016" EFFECT_SIZE="13.432098765432098" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="3" LOG_CI_END="1.6958505743503185" LOG_CI_START="0.5604371786167041" LOG_EFFECT_SIZE="1.1281438764835112" ORDER="8955" O_E="0.0" SE="0.6669474490408784" STUDY_ID="STD-Frazier-1999" TOTAL_1="91" TOTAL_2="20" VAR="0.44481889978213507" WEIGHT="11.783386388530756"/>
<DICH_DATA CI_END="28.548433208650504" CI_START="2.241804288601282" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="3" LOG_CI_END="1.4555822783433663" LOG_CI_START="0.35059769564052057" LOG_EFFECT_SIZE="0.9030899869919435" ORDER="8957" O_E="0.0" SE="0.6490734136415512" STUDY_ID="STD-Schofield-1999" TOTAL_1="72" TOTAL_2="75" VAR="0.4212962962962963" WEIGHT="17.795318219413794"/>
<DICH_DATA CI_END="2171.9215205304163" CI_START="4.776819720671448" EFFECT_SIZE="101.85714285714286" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="3.336844128552007" LOG_CI_START="0.6791388511232106" LOG_EFFECT_SIZE="2.007991489837609" ORDER="8956" O_E="0.0" SE="1.561149235814973" STUDY_ID="STD-van-der-Sloot-2004" TOTAL_1="14" TOTAL_2="15" VAR="2.437186936485674" WEIGHT="0.911558266018359"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.80633430599496" CI_END="1.6347304292842053" CI_START="0.7692309497641585" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1213764937462618" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="60" I2="23.139340888946627" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.21344614676595128" LOG_CI_START="-0.11394325038079754" LOG_EFFECT_SIZE="0.049751448192576896" METHOD="MH" MODIFIED="2008-10-03 15:24:48 +0100" MODIFIED_BY="Liz Bickerdike" NO="3" P_CHI2="0.2526381027817204" P_Q="1.0" P_Z="0.5513833567208082" Q="0.0" RANDOM="NO" SCALE="148.92155378517626" SORT_BY="USER" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="517" TOTAL_2="536" WEIGHT="99.99999999999999" Z="0.5956884828035698">
<NAME>Overall mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.934989692894466" CI_START="0.4143552629619978" EFFECT_SIZE="1.5681818181818181" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7734199690660195" LOG_CI_START="-0.3826271405638837" LOG_EFFECT_SIZE="0.19539641425106788" ORDER="1" O_E="0.0" SE="0.6790677947220896" STUDY_ID="STD-Aaberge-2000" TOTAL_1="50" TOTAL_2="50" VAR="0.461133069828722" WEIGHT="6.889770332852371"/>
<DICH_DATA CI_END="3.019435302807228" CI_START="0.7468517105934018" EFFECT_SIZE="1.5016891891891893" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.47992572845175874" LOG_CI_START="-0.12676561995717092" LOG_EFFECT_SIZE="0.17658005424729395" ORDER="2" O_E="0.0" SE="0.35637350122601447" STUDY_ID="STD-Allen-1999" TOTAL_1="132" TOTAL_2="143" VAR="0.12700207237608813" WEIGHT="25.281471304020272"/>
<DICH_DATA CI_END="1.6081471013430209" CI_START="0.1663645348410211" EFFECT_SIZE="0.5172413793103449" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.20632577226043566" LOG_CI_START="-0.7789392499469853" LOG_EFFECT_SIZE="-0.28630673884327484" ORDER="3" O_E="0.0" SE="0.5787495511851565" STUDY_ID="STD-Burkhoff-1999" TOTAL_1="92" TOTAL_2="90" VAR="0.33495104299702" WEIGHT="16.841565217980165"/>
<DICH_DATA CI_END="1.3683437952939042" CI_START="0.3115216358340582" EFFECT_SIZE="0.6528925619834711" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" LOG_CI_END="0.13619522723838642" LOG_CI_START="-0.5065117852904036" LOG_EFFECT_SIZE="-0.18515827902600862" ORDER="4" O_E="0.0" SE="0.3775292806104331" STUDY_ID="STD-Frazier-1999" TOTAL_1="91" TOTAL_2="101" VAR="0.14252835771823114" WEIGHT="34.53856221547087"/>
<DICH_DATA CI_END="85.2030780302855" CI_START="0.12070204188872896" EFFECT_SIZE="3.206896551724138" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9304552842904308" LOG_CI_START="-0.9182853829804729" LOG_EFFECT_SIZE="0.506084950654979" ORDER="5" O_E="0.0" SE="1.6733643694486577" STUDY_ID="STD-van-der-Sloot-2004" TOTAL_1="15" TOTAL_2="15" VAR="2.800148312940304" WEIGHT="0.8869111312709462"/>
<DICH_DATA CI_END="9.729617842973918" CI_START="0.9138994990555294" EFFECT_SIZE="2.9819277108433737" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9880957825142882" LOG_CI_START="-0.039101560727260884" LOG_EFFECT_SIZE="0.47449711089351365" ORDER="6" O_E="0.0" SE="0.6033808041289401" STUDY_ID="STD-Schofield-1999" TOTAL_1="94" TOTAL_2="94" VAR="0.3640683947912864" WEIGHT="6.9130916057392024"/>
<DICH_DATA CI_END="3.7382687526100296" CI_START="0.26750350661701566" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5726705205794317" LOG_CI_START="-0.5726705205794317" LOG_EFFECT_SIZE="0.0" ORDER="8923" O_E="0.0" SE="0.6727789971063071" STUDY_ID="STD-Jones-1999" TOTAL_1="43" TOTAL_2="43" VAR="0.4526315789473684" WEIGHT="8.648628192666164"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.982674901388814" CI_END="1.829410717443274" CI_START="0.8108575492111662" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2179456025811228" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.26231121903285504" LOG_CI_START="-0.09105543558596269" LOG_EFFECT_SIZE="0.08562789172344619" METHOD="MH" MODIFIED="2015-02-11 01:26:34 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.546037178348908" P_Q="1.0" P_Z="0.34217432075381693" Q="0.0" RANDOM="NO" SCALE="170.91" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="623" TOTAL_2="430" WEIGHT="100.00000000000001" Z="0.9498778770231628">
<NAME>Overall mortality (as-treated)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.934989692894466" CI_START="0.4143552629619978" EFFECT_SIZE="1.5681818181818181" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7734199690660195" LOG_CI_START="-0.3826271405638837" LOG_EFFECT_SIZE="0.19539641425106788" ORDER="8938" O_E="0.0" SE="0.6790677947220896" STUDY_ID="STD-Aaberge-2000" TOTAL_1="50" TOTAL_2="50" VAR="0.461133069828722" WEIGHT="8.228797842402516"/>
<DICH_DATA CI_END="2.420081124853112" CI_START="0.55353181881572" EFFECT_SIZE="1.1574074074074074" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.38382992444552566" LOG_CI_START="-0.25685740940331214" LOG_EFFECT_SIZE="0.06348625752110672" ORDER="8939" O_E="0.0" SE="0.3763429113562584" STUDY_ID="STD-Allen-1999" TOTAL_1="178" TOTAL_2="97" VAR="0.14163398692810458" WEIGHT="31.215026526138473"/>
<DICH_DATA CI_END="1.6081471013430209" CI_START="0.1663645348410211" EFFECT_SIZE="0.5172413793103449" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.20632577226043566" LOG_CI_START="-0.7789392499469853" LOG_EFFECT_SIZE="-0.28630673884327484" ORDER="8940" O_E="0.0" SE="0.5787495511851565" STUDY_ID="STD-Burkhoff-1999" TOTAL_1="92" TOTAL_2="90" VAR="0.33495104299702" WEIGHT="20.114724995633022"/>
<DICH_DATA CI_END="2.864557777830755" CI_START="0.465350839963667" EFFECT_SIZE="1.154566744730679" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="7" LOG_CI_END="0.4570575863482475" LOG_CI_START="-0.33221949784383525" LOG_EFFECT_SIZE="0.06241904425220613" ORDER="8941" O_E="0.0" SE="0.4636252662390072" STUDY_ID="STD-Frazier-1999" TOTAL_1="151" TOTAL_2="41" VAR="0.21494838749519027" WEIGHT="20.79602674423458"/>
<DICH_DATA CI_END="3.7382687526100296" CI_START="0.26750350661701566" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5726705205794317" LOG_CI_START="-0.5726705205794317" LOG_EFFECT_SIZE="0.0" ORDER="8944" O_E="0.0" SE="0.6727789971063071" STUDY_ID="STD-Jones-1999" TOTAL_1="43" TOTAL_2="43" VAR="0.4526315789473684" WEIGHT="10.329489892022185"/>
<DICH_DATA CI_END="9.729617842973918" CI_START="0.9138994990555294" EFFECT_SIZE="2.9819277108433737" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="4" LOG_CI_END="0.9880957825142882" LOG_CI_START="-0.039101560727260884" LOG_EFFECT_SIZE="0.47449711089351365" ORDER="8943" O_E="0.0" SE="0.6033808041289401" STUDY_ID="STD-Schofield-1999" TOTAL_1="94" TOTAL_2="94" VAR="0.3640683947912864" WEIGHT="8.256651606859391"/>
<DICH_DATA CI_END="85.2030780302855" CI_START="0.12070204188872896" EFFECT_SIZE="3.206896551724138" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9304552842904308" LOG_CI_START="-0.9182853829804729" LOG_EFFECT_SIZE="0.506084950654979" ORDER="8942" O_E="0.0" SE="1.6733643694486577" STUDY_ID="STD-van-der-Sloot-2004" TOTAL_1="15" TOTAL_2="15" VAR="2.800148312940304" WEIGHT="1.059282392709841"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.631426970601533" CI_END="2.240581256425701" CI_START="0.6268439143642065" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1851138026489094" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" I2="42.072150792332486" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.3503606985625625" LOG_CI_START="-0.20284058607392147" LOG_EFFECT_SIZE="0.07376005624432054" METHOD="MH" MODIFIED="2015-02-11 01:27:21 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.12469969216060184" P_Q="1.0" P_Z="0.6012134927519627" Q="0.0" RANDOM="NO" SCALE="404.3131824503572" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="474" TOTAL_2="493" WEIGHT="99.99999999999999" Z="0.5226562473784345">
<NAME>Early post-operative mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="111.23809302221136" CI_START="0.24366084874121702" EFFECT_SIZE="5.206185567010309" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0462535350552145" LOG_CI_START="-0.6132142473503811" LOG_EFFECT_SIZE="0.7165196438524165" ORDER="8924" O_E="0.0" SE="1.562184539962885" STUDY_ID="STD-Aaberge-2000" TOTAL_1="50" TOTAL_2="50" VAR="2.4404205368990506" WEIGHT="2.727243209343116"/>
<DICH_DATA CI_END="3.9073722335400363" CI_START="0.41843682831393897" EFFECT_SIZE="1.2786666666666666" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.591884786006458" LOG_CI_START="-0.3783700984485309" LOG_EFFECT_SIZE="0.10675734377896354" ORDER="8925" O_E="0.0" SE="0.5699325219679977" STUDY_ID="STD-Allen-1999" TOTAL_1="132" TOTAL_2="143" VAR="0.32482307959680223" WEIGHT="31.28533915872515"/>
<DICH_DATA CI_END="73.80257342864338" CI_START="0.11929602531924287" EFFECT_SIZE="2.9672131147540983" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8680715055408446" LOG_CI_START="-0.9233740258240095" LOG_EFFECT_SIZE="0.47234873985841747" ORDER="8926" O_E="0.0" SE="1.6397089230019475" STUDY_ID="STD-Burkhoff-1999" TOTAL_1="92" TOTAL_2="90" VAR="2.6886453521722067" WEIGHT="2.8522367629761654"/>
<DICH_DATA CI_END="1.0337253436428346" CI_START="0.07526128857982058" EFFECT_SIZE="0.27892561983471076" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.014405163917251728" LOG_CI_START="-1.1234283502160645" LOG_EFFECT_SIZE="-0.5545115931494063" ORDER="8927" O_E="0.0" SE="0.6683690385686426" STUDY_ID="STD-Frazier-1999" TOTAL_1="91" TOTAL_2="101" VAR="0.4467171717171717" WEIGHT="57.83442558369887"/>
<DICH_DATA CI_END="213.08962562967247" CI_START="0.6330537858015809" EFFECT_SIZE="11.614525139664805" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3285623063943444" LOG_CI_START="-0.1985593896911923" LOG_EFFECT_SIZE="1.0650014583515761" ORDER="8929" O_E="0.0" SE="1.4844437937347896" STUDY_ID="STD-Schofield-1999" TOTAL_1="94" TOTAL_2="94" VAR="2.2035733767577343" WEIGHT="2.701790912435519"/>
<DICH_DATA CI_END="85.2030780302855" CI_START="0.12070204188872896" EFFECT_SIZE="3.206896551724138" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9304552842904308" LOG_CI_START="-0.9182853829804729" LOG_EFFECT_SIZE="0.506084950654979" ORDER="8928" O_E="0.0" SE="1.6733643694486577" STUDY_ID="STD-van-der-Sloot-2004" TOTAL_1="15" TOTAL_2="15" VAR="2.800148312940304" WEIGHT="2.598964372821178"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.394435404544631" CI_END="8.660406728821615" CI_START="1.6311329442399345" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="3.758493677778126" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.9375382887765747" LOG_CI_START="0.21248935932159863" LOG_EFFECT_SIZE="0.5750138240490867" METHOD="MH" MODIFIED="2015-02-11 01:27:27 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.8800899679050005" P_Q="1.0" P_Z="0.0018786578932468707" Q="0.0" RANDOM="NO" SCALE="689.4220235872024" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="623" TOTAL_2="430" WEIGHT="100.0" Z="3.1087733253976095">
<NAME>Early post-operative mortality (as-treated)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="111.23809302221136" CI_START="0.24366084874121702" EFFECT_SIZE="5.206185567010309" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0462535350552145" LOG_CI_START="-0.6132142473503811" LOG_EFFECT_SIZE="0.7165196438524165" ORDER="8945" O_E="0.0" SE="1.562184539962885" STUDY_ID="STD-Aaberge-2000" TOTAL_1="50" TOTAL_2="50" VAR="2.4404205368990506" WEIGHT="6.207950596749467"/>
<DICH_DATA CI_END="14.413649468863552" CI_START="0.6791499783679" EFFECT_SIZE="3.12874251497006" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.1587739560757617" LOG_CI_START="-0.1680343088047451" LOG_EFFECT_SIZE="0.4953698236355083" ORDER="8946" O_E="0.0" SE="0.7793737425976451" STUDY_ID="STD-Allen-1999" TOTAL_1="178" TOTAL_2="97" VAR="0.6074234306506604" WEIGHT="31.713958527469295"/>
<DICH_DATA CI_END="73.80257342864338" CI_START="0.11929602531924287" EFFECT_SIZE="2.9672131147540983" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8680715055408446" LOG_CI_START="-0.9233740258240095" LOG_EFFECT_SIZE="0.47234873985841747" ORDER="8947" O_E="0.0" SE="1.6397089230019475" STUDY_ID="STD-Burkhoff-1999" TOTAL_1="92" TOTAL_2="90" VAR="2.6886453521722067" WEIGHT="6.492470071656519"/>
<DICH_DATA CI_END="7.84085985750327" CI_START="0.36144183852928535" EFFECT_SIZE="1.683453237410072" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="0.8943636916247723" LOG_CI_START="-0.44196157731267666" LOG_EFFECT_SIZE="0.22620105715604774" ORDER="8948" O_E="0.0" SE="0.7849640778906227" STUDY_ID="STD-Frazier-1999" TOTAL_1="151" TOTAL_2="41" VAR="0.6161686035786755" WEIGHT="37.80769912401802"/>
<DICH_DATA CI_END="232.14464510899373" CI_START="0.6654014684791777" EFFECT_SIZE="12.428571428571429" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3657586702273172" LOG_CI_START="-0.17691624501859407" LOG_EFFECT_SIZE="1.0944212126043618" ORDER="8951" O_E="0.0" SE="1.4935798316592703" STUDY_ID="STD-Jones-1999" TOTAL_1="43" TOTAL_2="43" VAR="2.2307807135393345" WEIGHT="5.7119545439163915"/>
<DICH_DATA CI_END="213.08962562967247" CI_START="0.6330537858015809" EFFECT_SIZE="11.614525139664805" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3285623063943444" LOG_CI_START="-0.1985593896911923" LOG_EFFECT_SIZE="1.0650014583515761" ORDER="8950" O_E="0.0" SE="1.4844437937347896" STUDY_ID="STD-Schofield-1999" TOTAL_1="94" TOTAL_2="94" VAR="2.2035733767577343" WEIGHT="6.150014215705468"/>
<DICH_DATA CI_END="85.2030780302855" CI_START="0.12070204188872896" EFFECT_SIZE="3.206896551724138" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9304552842904308" LOG_CI_START="-0.9182853829804729" LOG_EFFECT_SIZE="0.506084950654979" ORDER="8949" O_E="0.0" SE="1.6733643694486577" STUDY_ID="STD-van-der-Sloot-2004" TOTAL_1="15" TOTAL_2="15" VAR="2.800148312940304" WEIGHT="5.915952920484834"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.6255243322168925" CI_END="85.72458917929201" CI_START="-35.284020434935584" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="25.22028437217821" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2008-08-07 14:46:36 +0100" MODIFIED_BY="Liz Bickerdike" NO="7" P_CHI2="0.42900200026308144" P_Q="1.0" P_Z="0.4139394675554209" Q="0.0" RANDOM="NO" SCALE="343.18334589743387" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="64" TOTAL_2="65" UNITS="" WEIGHT="100.0" Z="0.816980695950676">
<NAME>Exercise tolerance</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="80.65993257919483" CI_START="-54.65993257919483" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="457.0" MEAN_2="444.0" ORDER="8930" SD_1="152.0" SD_2="191.0" SE="34.521008096520006" STUDY_ID="STD-Aaberge-2000" TOTAL_1="50" TOTAL_2="50" WEIGHT="79.9667469308554"/>
<CONT_DATA CI_END="209.17940689869147" CI_START="-61.17940689869147" EFFECT_SIZE="74.0" ESTIMABLE="YES" MEAN_1="519.0" MEAN_2="445.0" ORDER="8931" SD_1="157.0" SD_2="212.0" SE="68.97035249880578" STUDY_ID="STD-van-der-Sloot-2004" TOTAL_1="14" TOTAL_2="15" WEIGHT="20.03325306914461"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.3203678627795252" CI_END="19.378118667253062" CI_START="6.82413186998677" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="13.101125268619917" ESTIMABLE="YES" I2="24.26353077884782" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2008-10-03 15:24:29 +0100" MODIFIED_BY="Liz Bickerdike" NO="8" P_CHI2="0.25052617791746756" P_Q="1.0" P_Z="4.299441212345726E-5" Q="0.0" RANDOM="NO" SCALE="69.14821729254565" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="107" TOTAL_2="114" UNITS="" WEIGHT="100.0" Z="4.090769585488837">
<NAME>Seattle Angina Questionnaire - physical limitation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="18.551962182733053" CI_START="5.448037817266947" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="51.0" MEAN_2="39.0" ORDER="8932" SD_1="25.0" SD_2="21.0" SE="3.342899274891832" STUDY_ID="STD-Frazier-1999" TOTAL_1="93" TOTAL_2="99" WEIGHT="91.78264724910511"/>
<CONT_DATA CI_END="47.29705486959544" CI_START="3.5029451304045622" EFFECT_SIZE="25.400000000000002" ESTIMABLE="YES" MEAN_1="52.1" MEAN_2="26.7" ORDER="8933" SD_1="30.4" SD_2="29.7" SE="11.172172061485115" STUDY_ID="STD-van-der-Sloot-2004" TOTAL_1="14" TOTAL_2="15" WEIGHT="8.217352750894893"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.554935424633445" CI_END="0.6314745651408229" CI_START="-12.489536318605765" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.929030876732471" ESTIMABLE="YES" I2="92.03500483134347" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2008-10-03 15:24:35 +0100" MODIFIED_BY="Liz Bickerdike" NO="9" P_CHI2="3.951681264713347E-4" P_Q="1.0" P_Z="0.0765092139019644" Q="0.0" RANDOM="NO" SCALE="124.86316678727536" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="107" TOTAL_2="114" UNITS="" WEIGHT="100.0" Z="1.7713097084640785">
<NAME>Seattle Angina Questionnaire - angina frequency</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.921135882119406" CI_START="-3.9211358821194064" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="53.0" MEAN_2="48.0" ORDER="8934" SD_1="32.0" SD_2="31.0" SE="4.551683578110714" STUDY_ID="STD-Frazier-1999" TOTAL_1="93" TOTAL_2="99" WEIGHT="54.07970219860306"/>
<CONT_DATA CI_END="-9.118671598414965" CI_START="-28.48132840158503" EFFECT_SIZE="-18.799999999999997" ESTIMABLE="YES" MEAN_1="40.5" MEAN_2="59.3" ORDER="8935" SD_1="12.9" SD_2="13.7" SE="4.939544031395533" STUDY_ID="STD-van-der-Sloot-2004" TOTAL_1="14" TOTAL_2="15" WEIGHT="45.92029780139694"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="26.762804176396934" CI_END="9.0281202676187" CI_START="-4.643266065806611" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.192427100906044" ESTIMABLE="YES" I2="96.26347077305923" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2008-10-03 15:24:41 +0100" MODIFIED_BY="Liz Bickerdike" NO="10" P_CHI2="2.3002732274512994E-7" P_Q="1.0" P_Z="0.5295954992840897" Q="0.0" RANDOM="NO" SCALE="138.98689632804505" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="107" TOTAL_2="114" UNITS="" WEIGHT="100.0" Z="0.6286236160263337">
<NAME>Seattle Angina Questionnaire - quality of life</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="19.780316836988867" CI_START="4.219683163011134" EFFECT_SIZE="12.0" ESTIMABLE="YES" MEAN_1="54.0" MEAN_2="42.0" ORDER="8936" SD_1="27.0" SD_2="28.0" SE="3.9696223493691782" STUDY_ID="STD-Frazier-1999" TOTAL_1="93" TOTAL_2="99" WEIGHT="77.19169093233964"/>
<CONT_DATA CI_END="-16.68682386399394" CI_START="-45.313176136006064" EFFECT_SIZE="-31.0" ESTIMABLE="YES" MEAN_1="32.7" MEAN_2="63.7" ORDER="8937" SD_1="20.5" SD_2="18.7" SE="7.302775075923112" STUDY_ID="STD-van-der-Sloot-2004" TOTAL_1="14" TOTAL_2="15" WEIGHT="22.808309067660364"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-02-11 01:56:05 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-02-10 07:56:12 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeEAAAL9CAYAAAActt5zAABxL0lEQVR42uydAYRVzf//vyRJkkiS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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-02-11 01:56:05 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtYAAAEyCAMAAADp82f9AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-02-11 01:56:05 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAY0AAAKfCAIAAAAdMwOLAAAmpklEQVR42u3dwW4USbb/8ZKQEAsv
WPgJeAZWCLGCFe9EL1lYopd+C8QjXMG9y2FW7BB37CuahRf0zO4yY+WtwvPvv9vOKGdlRUTFyfj8
VBoxhfvnJPPEN09ERp6zWhERta+BiKhV4RQR4RQREU4REU4REeEUERFOERFOERHhFBHhFBERTtEC
o+d6GDkhhFPULqRu/IEIpwinCKeIcIpwipYUPSBFOEVEOIVT1PakUnwSTtHe0fMzfjJGkZUvwilq
nSY4RThFOEU4RTiVKS5BinCKMkWPbiCEU0SEUzhF7WZq5n2EU5Rz3mcdnXCKmgud0s44RThFOEU4
RVCVaUbpVIs0cUB5aCKQCKeol2SKCKcoAKdkaoRT1DSqBCThFJVKebLvnyLCKep0Ukk4RVQkWXNO
xIMgoAw0kUwRTlHrUzPrU4RT1AunoIpwigLkU9anCKcoa/RACeEUEeEUTpFMjXCKlhs9o3/OaJvd
nHCKOoVUXprgFOEU4RThFPUWPQVWkaxPEU4REU6ReR8RTlE7073SryKLT8IpypZPydQIp8iMknCK
aO/ZXyFzZ1uwiQNqehpIhFPUHKrM+winqF1OVXiSSDhF/YWO+uiEU0SFkj6Rj1NEmWd/2SEld8Mp
6hEopTMgnMIpon3x0T6qcAqnCKdipFQghVOEU5mnk+KTxAFlA4qzcTtlI5wims/WwQo9ThE1mKmV
owlO4RR1OoHa8g1O4RQRTs0cSyCFU4RTjc4oCaeo7ejJvSaNJoRTlDnrMdkpTW3CKeqLU95wxinC
qRjH7GzgFHU304kSRTiFU0SR0kDUxinqJXRKj/mh8JNEwY9T1NHUL8QcSqjjFImkMG+3VJj3GVY4
RfKptlBlEOEULTyBujM3KZfymFHiFFFfY8lJwClqa0AWzU0ixqT1KZyiXkMzd3Dq4YxT1PU0p9wS
dblVJOtTOEULz3SKznSKPkkswRfjCKcoQD7VYAJVM5+yPoVTREWSQScEp6ijlCpLFJV+kkg4Rb3P
+9TzBFacol44VW21u+giumGFU7TMDKL0k8SgbCWcogCZWuc5IOEUyQFbdybnlDKMzKFA1U2JCeEU
ZUNJhWp2ZmeCDado+Zyq8K6PHBCnqCNODQGrGsjUcIrajh4rxziFU0SFwFq0qLGzjVPUC1AqT9YI
p2hRc5xyy9I1e6B7kohT1C/F+uFUnaqBgsoJpUZJV2LHg/roOEVdRo93UAinKMr8rudAMu/DKcKp
YJmaMYVT1CKqStcdzvsksQJQDCucoubmOBUCKeOTRJzCKaLu5qoWp3CKek/ZQjgTTlGM2V/jWQ/h
FJlStT47C5oDknNKraMqCqTkgDhFXXAq7rtyOIVTFGCao04eTuEUUWa8DgV65KA2TlGnmVqJrKdC
xRjCKWoibm5nKI1PoHAKp6ijoLnzz7kglZcmOIVThFOtc2qwioRThFPtc4pwinAqp3mhZKrsWCrc
IweniOaMyezjv/TUzJNEnCIKFv04hVNErSeDOIVTRMtMoOpPV10455SIcIro0IE+FK7tZxzhFDU6
8rd/05pzpeFkQOEUUfsENKxwimh+plO0bJZ8Cqeo9cHfvnPph31CAqeoubgpMVbLORNOUV9BUyhn
Kec8alK617xQwSmiDBwU/DhFvQz7oq+hhOgMiIA4Ra1DqtCYL/GuXPapWdxeXjhFONUop6rNKAmn
CKcIp4gmR08JlJR2LtS/T3qFU0QBckCowikinMIpollzqBIvuBSqvlKIU4M6eThF7ecm5boWh3hz
kHCKOp1Ded5HOEU4VWQWDKw4RY2iqvH3Zra8LZz39WY5IE4RlQUuTuEUkVkw4RRVHJMlJlAVajmF
q0FKOEW9z+8EP04R4RThFLUQPaHmUDXrDhtZOEWLzU1KOB+qmp3BhVOEU4RTRHXnUBWcI86CyTml
huZQpWdnRZ3lgDhFVGPqilM4RdQLqowpnCJqiFP6YuEUUYFwhxKcIiLCKWouPRnidK+qk6mJDZyi
VkIn9Yc2nW/0BLQpAacIp9pyTj2My+sMVThFOIVTOEU0L3oi1EvAKZwiCpP9DcVKu4AUThFly9Gu
/9/2U0vCKSqSpLTsTDhFnUIqL1BMowinCKcIp6i36NFjinCKiHAKp8hc1VwVp6iPeV+5x/xCVKQJ
AsqTQbTvTDhFOBWAU9b+cYqgql3n0VDP2CanhDPhFOVMHxrvXrXdYR//cs6EU0SEU0Rtz1VLrE+Z
8eEUBZj6Ne4crlYy4RTlHJklGnaWdsYpnKK+OBVizOMUThFOBRjzN0rlZR9LIIVT1C6qrEkTThER
ThF1FfHencYpMubbdI74jJJwijKMzIjOnvfhFGXIIHAKpwinmrsGU76EqrxA8YwSpyjDgGz80liT
JpwiyRQRTjU57K1PFSqSN5SsbFWuGhfhVIuQCpRTSKkIp3AqQugEqedJOEWd5lOBI14fB5yi2VfC
pK+ysz6jOEW9pIFRnHEKp6jrCVSU9anrVoX2eYIUTnU07J2T0lTN2LzP2j9OdTSB8rY9EU7F4NQQ
ZyndszPCKZwKcMxbvmnNmXCKsqEq6L4EnCKcIpwinCKaFz2h1qfUosEpmpk7xHqqHff1Yy9O4xR1
x9ZAzjiFU9T7jC9jDlh6zyRU4RRlG59RsqpwzmrR4BRlG5maOBDhFE5BFeEU7TEyI740E6hegnd9
cIoyjEkXJVzeam8qThHhFE45obRfMjgUqDlXwhmncIo6zU2y13goWj3C+hROEU61zinCKcIpnCKc
WvyViLYlPcocSt92nKJsGQQR4RROOc9FzrznfTgFVeZ9+afV+mLhFGWIdblJBWcZMU6ROZQ5FOEU
NYOqKD3Q9W3HKco29Qs6V218xUcOiFMkys1Vi1xBy/M4hVMZjjbXkZdzrjDmy5XimvIlTlFsTsUa
P0ZmTWrjFC3/bqz2AOEUuRsXvB8MQWpmDX9+H9v6FFEv7A5U40H1CJxqZeTU6azpWuMUTlFfI9PZ
wCmc6nT8bPlGlOeM+FBr/9cNrU/R4YdNiUd+2Tml9gDhlHyqyDWWTA3em8Epoj7z1go5oOwSp1q8
1Ue5Igvo3xfIucR5xilqZdYQaOWrtHPo2PC8D6cWy6lyd+PofUbD5YA4hVPNLaD0TBPOW8zN+8is
oQm2ojbhVNeosi8Bp3CKmlvdoLg5oE7LONXR7KzamLdjiHAKp9q6G+uFRziFU/H6jLbsvKT96DhF
rcyhYuE1qHOI/n3eHMQpBMycR7TvXGjMe8MZp0iUt342Sr/51Pnlw6m2kp1AGYTssrSzalw41WkS
UXRk2pdAOEWtZ2rlZmelPRvv4Uw41RxWhjibPGM56+GMU5RnZIbbjx7RWQ/ncMeMUziVc17ZuDMF
zQEFAU5RsKwn1ztV9ZNZnFpaLDoh5I6FU+7GTbMVtetwKkptMnEgyrM5e7ul0Jkv9wA0ymoDTjUH
lEKVdjvnVNx6CbF6ZeNUL5AKdzcOnfWEmJ1FjDqcwqkm7saD9alFBF6IR8ziwJ2tx5EZ651E1MYp
d7Ye7wehndVLoOVnEIXSwBDOOFUtB8Spju7wJXYe6y0cC1XVrqD1KZo649v+JU5lTx96fl7heR81
F4s4RThF3RFwKLn276lCfVSZ9xE1R+2hWBXmXM76tuMU5Z9RBnI2V8Upaogjpdd3Y6Eq6Np/9pMT
LlPDKdp3muPN20LO+mLhVIBh3+zdeEnnuX1nwxOn2pqjVch3XG6qQ22cwqlW7saBnp3FjQq9snGq
C1SVPuBw783o4YxTlG2OViIcQ7x1UfPZmYw4xJ0Sp7pL0zp/vy86TcrdF+1LoGXm9hHreQZtN29f
Ak61OPUL4byMKXb7zuSELj/rodDzPrGBUzjVVw4Yi1N2wOFUR5wqtBdJz846zoYnTi0/N4n1fmwF
57jvJNY5G23SAKd6ydRK1xov91Su5/3opVEyep4bPOE4hVPNjSLrMoeaqDb7ohJONRGFQbsWRwd3
lC5hOCV2SXYZYH5d8x6GU7TbnY1wKlCXPZxa+gWwyoNTh8jUcIr2yqeoaMSXOO2FnIPOKHGK5ID9
poF9VjQWBO0O/uzOQ5xdTvZPyeJxqukb5hCtml32uK/z3kz7+xK2m1T4FThFtWmCUxHP8+jwzMhB
61O0cE4NkeslOM8hV0WQoilUqZPnfkA4Rb1HfAmUNL6l+zZVzfto5t045F1ODV/CKahqc0YZtHcL
bTnP8inaLX3QY6r0qR467uGsLxY1es8sXScvBKrUSwiat+IUTrWYA8bNLgPVS8Apam4+Ei405VOh
M2KcMn4oW7LWvnPEjBincCrPrbLQixeFxrw08HZq3OPdBSkWmU+Vfjus9LpJzxUsCafMR1qfj5Sb
BYfr41CnB23jHMAp6ohTsZxL73Kyz5OsmzSdm4SunxMiU8OpLuZ9LoocsNrZwCk68D2TRiO+xGkv
7dxzD1qcWjindAZcWA5oXwItClV6t5ir4hQVZ4oZZelh3/nav3kfGfN9jfmIe76so1PTyVq3Y97z
PpyiPDQZopWIQpMh7CpSlH6uONXcBKrQ+MGp21OnxvclVNiPHuVJC04tnFOlUaV3i6wHp3CqyD3T
CQ8KqW5RJXAbuxJxUBKxb/sQsGZWnbMxWJ+iZSM148isViEgVs2scJV5cIpauWdG7IvleR9OUf48
os/xE3Fk4hRO9TWEhjJV0gP1lSvtfP1XFBr2wfq4eG+G5s10ck3T9EOm5Uw4nIilcmoovwqLU4uJ
OpyiOTRp/NJAVeXYGAo8ScQp6gisIfq2h8569BnFqb6A4pzgVMgYFg3WIMyh2nQO2isbp6gVTsV9
ByVijYcSk+spX+IUBUZVxHdQ7POsQECcMh+Rm+BUx6PDiWgk5VEnbwjbuaCas3V0wqmZh+0dlFjT
dpyi5jIIZxincIranTXYM1ltDlXh3WmcImqFrYN3EqsQMFC7bJyibCOz/Uq7oWv7lTZv+UklTrU4
7KN0VQrHqYhAqXnAzRZKx6mF5yax2FrH2foUTlEvnIrYzSHovK8aW837aE7ENH6fX8D9oH1nwqmO
Rmb7PdqginAKpzJXBSk3L4tYga/+7KyrXBunGp33eT+WUtcrxDtVOGUyMh9VrjVO4RT1tbSxgH0J
7TsH3U2GU1DV3X3e3tTO3/3EqZYuQ+FwLH0rxqkF5Mg4RYfMetScwymcoh45tYDUNYpzXvyV3v+B
U8sfP0OQzgVU+U7Tc6aGU2ZnDd2Nw93nQ3MqEAFxyuys32Hf7V6K0jV/cAqn3OflJqWuoHkf1b5n
lrvPR6zogoA4RbKeMPf5QM/7KszO7EcnnFr+fT707Mz6FDUUMXVmlCEGp/Wp2APEiejkFhqCreFq
GZdeU7NLA6egylmNdL2i7KHHKSNq3xuy0ys2Bvs8qR2UROzTO9TtABxudoZT5N67s3PpdxI7b2Jc
8x6GU7Q0VJXbQ19zd37nuyusT9G+s4ZyT6NwCqdCDhAnoqmsJ9Au4eth1L5zxKbtgbIenOpuauai
UIXYMO8jsUhNx4Z1dGqFJkEJyBmncMrdmHOkMR+o5g9OkTEvNymYwre8OIBTzQXNEKoDcKFhWcgZ
p2KPDieikawnVt3hiBUI7B7AKeqIUySLxymcKjLZca0p4t0RpxqdRpWAFFTJenCKmr5nZuSUt+1q
cn8Z71HiFNXO1MotZ3CuvybgvRmaGY5xH/ZxDlSXIt69FibagVSUWDRHqzb7C1rrNeN9F6dwigRe
6/GMUzjV4uoG5y0oCVEtHqeWPAOPBaly44fzEOr9O5yi/LdNNAnt3OF9F6csQKBJ086EUziVM1Pj
XNq5W/zhFFRRjMsX+hmL9SnaLVxcbpwqnall7xQrcJd5/yGcWpKzIWFqRsHuYR0SEKeWzylpGh1k
Rnk9/Mz7oGo326K7mb2KHG5DpnoJtFegN86pIVEpNGPpmM6d4+5HxynJVEP51Og3Jerw9excevCX
iLfsbMWphXNqqP5+LE5F4dSN8JBP0YFRVZOA5bpXcS46WltGAU61OOBdFKowcy+aTxVp6Sgalhrf
CIhT9ROo7McscClnGsi59FJgn7XJcKrRMR/iblwtyjt3zr47oUKunZetOLXY3L707hs0qeMcPcW2
LwGnDjx+ACU0qgLV9sMpEZPzzsk5xMpXuJ3uONXosC8KFGc79D2swwRQ4PYS5T1XrcWphdzFnYhO
ODXke0ekxKyB8wFTqpYPGKfamu613/GRWgiSQjRpFlU41WJ6n/0aX7/YTrV5X2lO2ZfQSywGKFpW
Zg7FuWYkqJNHi+VUzRyQs6k6TrWbpLQ/fnQtDjqHqhzPg/dmyJhfvHMgmtz+t+s3Q4cfP7qr13Eu
HRv6YtH89L7b8UN1riBO0b5ZD1G1uWrRjvDqeeJULzlgz85BZ+5FIg0pFoyq0C9zcA66Qo9Ty1+A
CHE3RpNq7Ii4wmg/OjU0awCUiGlOuD30OIVTLeaAnC1i4NTy8+ToswZKDftA8z6cWmwgqmZHlWfu
efej6+PQEaeG5uslDKrZlXeuMHOPEnU4tVhOhavVT5Vn7hX2o+diq8BtEVWuCLk74hQ1mqlxXlim
Zt5H5n39XspOz4BQaCEKi96RKPrsLC5YcWpRUXj9yVHRAMrL1kIbJjkX5dT1g2z/ASVOtcWpokFZ
IhDzbkHkXAdVdc5Gxn8CTjWXTxXCU6FhgyalOVVuzxdO0eE5VW7BC00q51PVog6nSD7FefmcGqxP
LZVTFXYPVKgNYP9UrJ1ZN6waf/Udp3rEovNAIW/nTgQR4RQREU4REU4REeEUERFOHfAUE9FdwqlD
coozZ877OOMUTnHmjFM4JRY5c8YpnOLMGadIxHDmjFM4xZkzZ5xqmVOXl99///31t29Pz88f/u1v
q7Ozo99+e/z9+y+Xlxd7On//5/fXZ6+f/vXpw/98uPqP1dGHo8d/efzLf/9y8WNf539+/372+vVf
nz79z4cP/2O1+nB09JfHj//7l19+XDjmnMfMGaea4NQ//nF6fn68xtPtzxpbf//7r7OdT7+eHv/X
8TpQbn/WAfTr/8x3/np6+l/Hx2PGqzUC/udXx5znmDnjVBOcWidNo4S6/ln/zAzn9e1rNFauf9Y/
M8N5nYDcZbxa/4xj3vOYOeNUE5xaZ1J3Qurqk8qqUs7re9qd4XL1Sd3fUs7rrGSa8SqVoThmzrs6
H4xTU35jzaNKddDb58vt/5DLy+/Xp3vv36+ePVs9eLD5vHy5+vjx5gTwX//6NtH5+z+/pxLv0VT8
2/9Odf7n9++pqdPoZOp/vznmOcfMuQlOTSzXXe2oRutD7/nlnf+Q339/fZ1Ejx5trsK7d6u3bzd/
ePJk0uxv1Pn12euJ4bIlDx91Pnv9ehfj8ZmUY+a8k3NbnLqdkqSabm75yes/MIy1xpsOx9Kc+vbt
6egU7/PnzUHev3/z+99+ezzR+elfn45ExpXGIubxX6Y6//Xp053G/F8eO+Y5x8y5UU6lxv9tFuz0
k9NRUp9TV1sQbnw+fVo9f7457Ddvbv7V2dnRROerh8HTI+bow1Tnq8f50z8fjhzznGPmfHhOTR/V
+5NiV07N85nHqdFk6sWLzbV49Wp8NX2i83isXNetoJnofDveju8wdsxzjplzE5waLTdz+8stqdOU
n7zzvzosp0bzqXv3Nof35csIpORT8in51IHzqXlfzuPLxGX7Q61PpT7Wp6xPWZ86wJO17Uvgu65P
TVy0mo6Sys/7rj5Xmr7b07Mzz/s876vHqdGHdLs+77vxA9Of9905Fd3+24cc+6e2c8r+Kfun7J9a
7H70Rv5d9qM7ZvvRQ+5Hr7NO3z4uvd/nmDn3nk+FSOt+1kt4mK6XcDLbeX1/G38K8zPxPjmf77zO
UFLP0dbfn5845jzHzBmnGpp+pupPja5J7eScqgQ0ujqwk3OqltPo+o5j5rynM04FXibjzLkTZ5zC
Kc6ccQqnxCJnzjiFU5w54xSJGM6ccQqnOHPmjFOH5RQRTRFOyac4c5ZPkVjkzBmncIozZ5wiEcOZ
M07hFGfOnHEKpzhzxinKf11T9RIuLy+adU7VHvhxsa9z6m37ix89Okc8zyWOGacOzKmf9aeO0/Wn
fm3Q+evpaaqY7zo0U1Uxpziffj1Nla9dD6dUHcilOkc8z4WOGacOyaly9TzLOauNWcdZ3VScaoJT
5eqjl3NWa7yOszr0sTmV6rK3/z9htBdOtX4z79+vnj1bPXiw+bx8ufr4cX6/mXLOerfUcdbXJzan
RrtdZeHUKHq2/5a8/fsePdocwLt3q7dvN3948mR+/75yznrh1XHWJ7ELTqUa/G3p3zc00w/58+fN
Qd6/P78fcjlnvYXrOOs7vXxO7dQbecqMshCnRnvMfPq0ev58c6hv3tz8q7Ozo4M7p/q1pD4fjqY6
j3coSY+fow9Ldo54nssdczBOTcTTPJRsX/ka/S3bv7zz7I+mPC9ebBxevRpf8z648+1oO/5zUY7b
PzDReXzkbLVesHPE81zumONx6nadmhQsUj82nVPD1v7vU76ckfXcu7fx+fJlBCV75lNZnOVT8in5
VP58avt/u9M5yv5lahUp9dl/fWp/Z+tT1qesT+28aaDOvK/O876rz5Wm78ms7Ox5n+d9nvfl4dSW
533z5n119k9tp8k++6cyOts/VcfZ/qnYz/uCyn70Kc72o0c/z/ajL5NTg/f7/izv90U/z97vWyan
hn9XNXiYrmpw0qDz+s6Zer6z/v78ZL7z+m4//kzq5zTk5Lwv54jnudAx49SBOTWkq0SNrhw14pyq
MTS67rCTc6ou0uhayeKdI57nEseMU4fnFGfOnHEKpzhzxikSi5w54xROceaMUziFU5w54xROcebM
Gada5hQRTRFOyac4c5ZPkVjkzBmncIozZ5wiEcOZM07hFGfOnHEKpzhzxinKf11Tb65f/Lho1jn1
TvyPi4sOzwbn60pV6bi8vMCpqJw6/XqaKgW7DqBUTcXDOn89PU0VmV1jK1Wtcalng/N1/ax6dpyu
evYrTsXjlDqT0c8G5z/laMWqyOLUwTilbnf0s8H5RiZVqCr/YTg1caf8lH/Grv/5H11qplgV7Tej
D0r0s8H5xprU9ene+/erZ89WDx5sPi9frj5+nN/l6JCcmseafTh1ZyPSyv379JWLfjY4X9eNrpGP
Hm0G1Lt3q7dvN3948mR+18jmOLWFAqOt0q//7/YEZ/vrjqMt10tzSp/e6GeD83WlunB//rzxvn9/
fhfuMJza3qV915bIjfRDHu/2kY6Yow9HB3dO9RFJfT4cHS34bHC+rtHORp8+rZ4/33i/eXPzr87O
jgJwajS1mUiBGf/JPpxKoXD7l3ee/fFYua5bQXNw59uRfHyH8ZLPBufrGk2mXrzYWL56Nb6avsB5
X2q5uhynbqy7z/hSPiWf6jyfundvY/zlywikYuRTszmV9z+Zfo6yf2l9ylpPD+tTqc8S1qdGZ1WV
OeV5n+d9nGc/77v6XGn6bs8w+6duT6C2z/K2/G1qhrjrvM/+qT9k/xTnYdr+qe2cirF/qjfZj77U
s8H5upa2Hx2n/pD3+6KfDc5/yte837dITl3d38afwvxMvE/OTxp0XmdVqWd/6+/PT066Ohucb2RV
o8/+/l+9hJnOOHVgTg3pSkCjqwONOKfqT42uSS3+bHC+sVY1Wn9qdE0Kp8JwijNnzjiFU5w54xSJ
Rc6ccQqnOHPGKZzCKc6ccQqnOHPmjFMtc4qIpgin5FOcOcunSCxy5oxTOMWZM06RiOHMGadwijNn
zjiFU5w54xTlv66pN9cvflw065yql/Djot1jTr3Hf3nZrrPYwKkmOHX69TRVCnYdQKmaiod1/np6
mipAvA7NVCXPwx7zz7pIx+m6SC06iw2caoJT6nnWOeZydSbLOYsNnGqCU+qj1znmcnW7yzmLjXY5
NXEHfaFFPv1m7nSO2G/mRh+U9+9Xz56tHjzYfF6+XH38OL8PSjlnsdE6pw6LyNTB6N93pYj9+270
lXv0aHOh371bvX27+cOTJ/P7ypVzFhvxOHW7nd+NLqQ3UrApXfxGkVSZU/oh1znmVJ/ez5833vfv
z+/TW85ZbITk1BQiTG+V3Eg/5PFuH+mIOfpwdHDnVI+Z1OfD0eGPebT3yadPq+fPN95v3tz8q7Oz
wzuLjTDrU3ce+mxOTaTk9ibyd355N39HY+W6bl3bgzvfjrbjO4wPf8yjKc+LFxvLV6/G17wP7iw2
os77prNsy5RwJ04NY03kd/rSPbPZfOrevY3xly8jKNkzn8riLDZic2pKirQdSTtxasZszvpUlPWp
1Gf/9an9ncXGQji1JUXKPu/zvG9Jz/uuPleaviezsrPYWMi87/pDuhnP+3aa99k/9YcWsH9qO032
2T+V0VlsNM2ppcqe48Mes/3o0WMDpw7JqcE7XLWO2ft90WMDpw7Jqav72/hTmJ+J98n5SYPO6ztn
6vnO+vvzkxaP+WdVg4fpqgYtOosNnGqFU0O6EtDo6kAjzqkaQ6PrDo0cc6pK1OjKUSPOYgOnWuEU
Z86ccQqnOHPGKRKLnDnjFE5x5oxTOIVTnDnjFE5x5swZp1rmFBFNEU7Jpzhzlk+RWOTMGadwijNn
nCIRw5kzTuEUZ86ccQqnOHPGKcp/XVNv219eXjTrnHon/sfFvs6p9/gvfvR4zJxxqglO/axedJyu
XvRrg85fT09TRWbXCEhVa5zifPr1NFUYdx30qQqTSz1mzjjVBKci1pmMWM8z4jFzxqkmOBWxbnfE
+ugRj5lzJE7VPLDK/WZudCt5/3717NnqwYPN5+XL1ceP2fqgZHSO2G8m4jFzxqltZyH1q0v077vR
/e3Ro80BvHu3evt284cnT7L1lcvoHLF/X8Rj5hyYU6lmfPunPKMt10tzKtVN9/PnzUHev5+/T+/+
zhH7IUc8Zs5ROTW9K/I8lNTn1GiHkk+fVs+fb/5Rb97c/Kuzs6ODO6f6iKQ+H46mOo/3PklH+dGH
JR8z56VxasaXE+eYd9Jw+5d3nv3RlOfFi43Dq1fja94Hd74db8d/Lspx+wcmOo/H91brBR8z5y44
NVrOZkqBm9Si1W2fKV/OyHru3dv4fPkygpI986kszvIpWY98Ks+E685/y05P5Xadze2/PpX67L8+
tb+z9SmrSNan8nOq5fWpG0/lrj5Xmr4ns7Kz532eynnet/MDuy1/3nWL03Do/VPbabLP/qmMzvZP
1TlmzsHWp5Yh+9GnONuPzhmnWuTU4P2+P8v7fZxxqkVODf+uavAwXdXgpEHndYaSeo62/v78ZL7z
+p48/uTo52Th5LyvY+aMU61wakhXiRpdOWrEOVXLaXR9ZyfnVPWi0RWNxR8zZ5xqhVOcOXPGKZzi
zBmnSCxy5oxTOMWZM07hFE5x5oxTOMWZM2ecaplTRDRFOCWf4sxZPkVikTNnnMIpzpxxikQMZ844
hVOcOXPGKZzizBmnKP91Tb1ffvHjolnnVO2BHxeOOcYVjOWMUwfm1OnX01TB1vVlTlU+PKzz19PT
VDHfNQJSVTEdM+fZzjh1SE5FrKyonmf0K6ieJ+1w9iNWqlYfPfoVVB99uON33PWLdjqM2YbTu8IU
7TcTsfOHfjPRr6B+M1NhsWs7z31+cqdWoJX790XspKZ/X/QrqH/fHE6N9uO7M1u5/n+3t+2b2Fp9
9PvSnIrYmVY/5OhXUD/knXOf2+P8BoymoGHGjzXSD3m8J0f6uh59ODq4c6pfS+rz4cgxt3UFIzof
eH0qldcU5dSwe9/2FD2nQ3D8y9Erel23Lu3BnW/H2/Edxo65rSsY0fkwz/tG2ZGFU7dpuA+nUlPF
6V/Kp+RT8qkw+dSWPKVQPjVjajZjgX/PL61POWbOkTg1Y/VnAetTnvc5Zs4B1qdSz/tSj+qmMGLe
877t8z77p/6Q/VPRr6D9U7TzE0/70R0zZ5xqnVOD9/scM2ecap9TV3eh8WclP9Pjk/OTBp3XGUrq
Odr6+/MTx9z6FQznjFMH5tSQrtczOodvxDlVy2l0fccxc97TGacOzynOnDnjFE5x5oxTJBY5c8Yp
nOLMGadwCqc4c8YpnOLMmTNOtcwpIpoinJJPceYsnyKxyJkzTuEUZ844RSKGM2ecwinOnDnjFE5x
5oxTlP+6Xl5+//3319++PT0/f/i3v63Ozo5+++3x9++/XF5eNOucqj3w42Jf59Tb9hc/ejzmiM4l
zjNOHZhT//jH6fn58Roitz9ruPz977826Pz19DRVzHcdmqmqmFOcT7+epsrXrodTqg7kUo85onOh
84xTh+TUOrUZ5cj1z/pnmnJWz7POMav1ilNNcGqd79yJkqtPKvep76w+ep1jVjv/8Jya9+smNlWe
99uztJbZqd/M5eX365Oy9+9Xz56tHjzYfF6+XH38eHOa9q9/fTu4s34zdY5ZL6KonJrerHTGb8/S
qm/Xvli///76Oi8ePdr85+/erd6+3fzhyZNJc7TKzvr31TlmvR3ncCo1YkdTm+3DNdXxfNRnV05N
SX+mvO5Yh1Pfvj0dnYh9/rzxuX//5ve//fb44M76Idc5Zr2y83BqC7nuzFlSP7a9ZfGdCJiXE+Xi
1K4dTNe62ihw4/Pp0+r5880//82bm391dnZ0cOdUv5bU58PRVOfxDiXp8XP0YcnHHNG53HneYd63
ZRxObF++P0e2r09l4dSdzZkzcmo05XnxYvOve/VqfM374M63o+34z0U5bv/A1PXB0ZGz1XrBxxzR
udx53otTt6kxj1PbfaZnPQfk1BTCTsx67t3bnIcvX0ZQsmc+lcVZPiWfipRP7bp2sxMypnxZglNb
VsSmTFR3fQ6YWkVKffZfn9rf2fqU9al216cmriVN5NSU9an6nNpnojpvX8KNp3JXnytN35NZ2dnz
Ps/72n3et/3x1sQxvOvzvl3Xp4bJ2522/MzoT9bZP7WdJvvsn8robP9UnWO2f2o+p2i27Eef4mw/
enTnpe1Hx6n/f3/zft81eb8vurP3+5bJqeHfVQ0epqsanDTovL5zpp7vrL8/P5nvvL7bjz+T+jkN
OTnv65gjOhc6zzh1YE4N6SpRoytHjTinagyNrjvs5JyqizS6VrL4Y47oXOI849ThOcWZM2ecwinO
nHGKxCJnzjiFU5w54xRO4RRnzjiFU5w5c8apljlFRFOEU0QU/GbvRBARThER4RQR4RQREU4REeEU
EeEUEVEpThERtaz/AyjV5Ms5hwNbAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-06-27 10:30:24 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-06-27 10:30:01 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-06-27 10:28:26 +0100" MODIFIED_BY="[Empty name]">Search strategies 2014</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-27 10:30:01 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL (The Cochrane LIbrary)</HEADING>
<P>Issue 6 of 12, June 2014. Search date: 11th June 2014 (N=91 records)</P>
<P>#1 MYOCARDIAL next REVASCULARIZATION*<BR/>#2 ANGINA next PECTORIS*<BR/>#3 ANGINA<BR/>#4 MYOCARDIAL near REVASCULARI*<BR/>#5 HEART near REVASCULARI*<BR/>#6 CARDIAC near REVASCULARI*<BR/>#7 TRANSMYOCARDIAL near REVASCULARI*<BR/>#8 #1 or #2 or #3 or #4 or #5 or #6 or #7<BR/>#9 LASER next SURGERY<BR/>#10 ANGIOPLASTY next LASER<BR/>#11 LASERS*<BR/>#12 LASER*<BR/>#13 #9 or #10 or #11 or #12<BR/>#14 #8 and #13</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE (PubMed) </HEADING>
<P>(1946 to June Week 2 2014). Search date: 11th June 2014 (N=160 records)</P>
<P>(((((((((((((((((("Myocardial Revascularization"[MeSH Major Topic]))) OR (("Angina Pectoris"[MeSH Major Topic]))) OR ((angina))) OR ((myocardial near revasculari*))) OR ((heart near revasculari*))) OR ((cardiac near revasculari*))) OR ((transmyocardial near revasculari*)))) AND ((((((("Laser Surgery"[MeSH Major Topic]))) OR (("Angioplasty, Laser"[MeSH Major Topic]))) OR (("Lasers"[MeSH Major Topic]))) OR ((lasers*)))))) AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) NOT (("Coronary Artery Bypass"[MeSH Major Topic]</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE (Ovid) </HEADING>
<P>(1980 to 2014 Week 23). Search date: 11th June 2014 (N=167 records)</P>
<P>1 heart muscle revascularization/ (21752)<BR/>2 (myocardial adj3 revasculari$).tw. (6704)<BR/>3 (heart adj3 revasculari$).tw. (779)<BR/>4 (cardiac adj3 revasculari$).tw. (1018)<BR/>5 (transmyocardial adj3 revasculari$).tw. (680)<BR/>6 exp Angina Pectoris/ (73730)<BR/>7 angina.tw. (54210)<BR/>8 or/1-7 (108113)<BR/>9 Laser Surgery/ (23158)<BR/>10 laser angioplasty/ (869)<BR/>11 exp laser/ (85517)<BR/>12 laser$.tw. (178969)<BR/>13 or/9-12 (198152)<BR/>14 8 and 13 (1277)<BR/>15 clinical trial/ (831522)<BR/>16 random$.tw. (873199)<BR/>17 randomized controlled trial/ (343012)<BR/>18 trial$.tw. (794983)<BR/>19 follow-up.tw. (825154)<BR/>20 double blind procedure/ (113517)<BR/>21 placebo$.tw. (197024)<BR/>22 placebo/ (240345)<BR/>23 factorial$.ti,ab. (22736)<BR/>24 (crossover$ or cross-over$).ti,ab. (68317)<BR/>25 (double$ adj blind$).ti,ab. (140313)<BR/>26 (singl$ adj blind$).ti,ab. (14231)<BR/>27 assign$.ti,ab. (235823)<BR/>28 allocat$.ti,ab. (82510)<BR/>29 volunteer$.ti,ab. (174246)<BR/>30 Crossover Procedure/ (39104)<BR/>31 Single Blind Procedure/ (18341)<BR/>32 or/15-31 (2874543)<BR/>33 exp animal/ (18627628)<BR/>34 nonhuman/ (4310562)<BR/>35 exp animal experiment/ (1674793)<BR/>36 or/33-35 (19829748)<BR/>37 exp human/ (14727333)<BR/>38 36 not 37 (5102415)<BR/>39 32 not 38 (2635053)<BR/>40 39 and 14 (495)<BR/>41 limit 40 to yr="2004 - 2014" (167)<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">ClinicalTrials.gov </HEADING>
<P>(http://www.clinicaltrials.gov/). Search date: 11th June 2014 (N= 17)</P>
<P>1 revascularization AND laser</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">metaRegister of Controlled Trials mRCT </HEADING>
<P>(http://www.controlled-trials.com/mrct). Search date: 11th June 2014 (N= 62)</P>
<P>1 revascularization AND laser</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">WHO International Clinical Trials Registry (ICTRP) </HEADING>
<P>(http://www.who.int/ictrp/search/en/). Search date: 11th June 2014 (N= 5)</P>
<P>1 revascularization AND laser<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-06-27 10:30:24 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-06-27 10:28:35 +0100" MODIFIED_BY="[Empty name]">Search strategies 2007</TITLE>
<APPENDIX_BODY MODIFIED="2014-06-27 10:30:24 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL on The Cochrane Library</HEADING>
<P>The search was performed in the web "La Biblioteca Cochrane Plus" available from the Spanish Minitry of Health (http://www.update-software.com/Clibplus/ClibPlus.asp).</P>
<P>#1 MYOCARDIAL next REVASCULARIZATION*<BR/>#2 ANGINA next PECTORIS*<BR/>#3 ANGINA<BR/>#4 MYOCARDIAL near REVASCULARI*<BR/>#5 HEART near REVASCULARI*<BR/>#6 CARDIAC near REVASCULARI*<BR/>#7 TRANSMYOCARDIAL near REVASCULARI*<BR/>#8 #1 or #2 or #3 or #4 or #5 or #6 or #7<BR/>#9 LASER next SURGERY<BR/>#10 ANGIOPLASTY next LASER<BR/>#11 LASERS*<BR/>#12 LASER*<BR/>#13 #9 or #10 or #11 or #12<BR/>#14 #8 and #13</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE</HEADING>
<P>(((((((((((((((((("Myocardial Revascularization"[MeSH Major Topic]))) OR (("Angina Pectoris"[MeSH Major Topic]))) OR ((angina))) OR ((myocardial near revasculari*))) OR ((heart near revasculari*))) OR ((cardiac near revasculari*))) OR ((transmyocardial near revasculari*)))) AND ((((((("Laser Surgery"[MeSH Major Topic]))) OR (("Angioplasty, Laser"[MeSH Major Topic]))) OR (("Lasers"[MeSH Major Topic]))) OR ((lasers*)))))) AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) AND "1997/03/14 01.45" : "2007/03/14 01.45"[PDat]))) NOT (("Coronary Artery Bypass"[MeSH Major Topic] AND "1997/03/14 01.45" : "2007/03/14</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE</HEADING>
<P>1 heart muscle revascularization/ (10008)<BR/>2 (myocardial adj3 revasculari$).tw. (3027)<BR/>3 (heart adj3 revasculari$).tw. (248)<BR/>4 (cardiac adj3 revasculari$).tw. (358)<BR/>5 (transmyocardial adj3 revasculari$).tw. (456)<BR/>6 exp Angina Pectoris/ (34927)<BR/>7 angina.tw. (27834)<BR/>8 or/1-7 (52088)<BR/>9 Laser Surgery/ (12756)<BR/>10 laser angioplasty/ (525)<BR/>11 exp laser/ (34582)<BR/>12 laser$.tw. (76994)<BR/>13 or/9-12 (84847)<BR/>14 8 and 13 (787)<BR/>15 clinical trial/ (426483)<BR/>16 random$.tw. (337348)<BR/>17 randomized controlled trial/ (119040)<BR/>18 trial$.tw. (296752)<BR/>19 follow-up.tw. (306510)<BR/>20 double blind procedure/ (64157)<BR/>21 placebo$.tw. (98580)<BR/>22 placebo/ (99069)<BR/>23 factorial$.ti,ab. (6886)<BR/>24 (crossover$ or cross-over$).ti,ab. (35815)<BR/>25 (double$ adj blind$).ti,ab. (77323)<BR/>26 (singl$ adj blind$).ti,ab. (6660)<BR/>27 assign$.ti,ab. (94832)<BR/>28 allocat$.ti,ab. (29752)<BR/>29 volunteer$.ti,ab. (89976)<BR/>30 Crossover Procedure/ (18704)<BR/>31 Single Blind Procedure/ (6639)<BR/>32 or/15-31 (1205353)<BR/>33 exp animal/ (113406)<BR/>34 nonhuman/ (2891884)<BR/>35 exp animal experiment/ (1184729)<BR/>36 or/33-35 (3131158)<BR/>37 exp human/ (5761289)<BR/>38 36 not 37 (2679515)<BR/>39 32 not 38 (1108623)<BR/>40 39 and 14 (312)<BR/>41 limit 40 to yr="2004 - 2007" (62)<BR/>42 from 41 keep 1-62 (62)</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 RCTs included&lt;/p&gt;&lt;p&gt;Outcome data for:&lt;/p&gt;&lt;p&gt;Angina severity: 7&lt;/p&gt;&lt;p&gt;Mortality: 6&lt;/p&gt;&lt;p&gt;Exercise tolerance: 2&lt;/p&gt;&lt;p&gt;Quality of life: 2&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Papers included: 20&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;Papers retrieved for more detailed evaluation: 47&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Potentially relevant publications identified and screened for retrieval&lt;/p&gt;&lt;p&gt;Total: 502&lt;/p&gt;" WIDTH="120">
<OUT TEXT="&lt;p&gt;455 papers excluded after review of title and abstract (generally due to lack of suitability of study design or intervention, or duplicate records&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Excluded 27, main reason:&lt;/p&gt;&lt;p&gt;Non-randomized 1; percutaneous revascularisation 11;&lt;/p&gt;&lt;p&gt;non-appropriate control 6; other interventions 4;&lt;/p&gt;&lt;p&gt;narrative overview 4; no control group 1&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;Papers coalesced into RCT studies (further publications of single studies grouped): 13&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>